Veradigm (MDRX) 10-Q 30 Oct 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Oct. 26, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Trading Symbol	MDRX
Entity Registrant Name	ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
Entity Central Index Key	0001124804
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		157,981,681
Entity File Number	001-35547
Entity Tax Identification Number	36-4392754
Entity Address, Address Line One	222 Merchandise Mart
Entity Address, Address Line Two	Suite 2024
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60654
City Area Code	800
Local Phone Number	334-8534
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.01 per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 218,701	$ 129,668
Restricted cash	6,209	7,871
Accounts receivable, net of allowance of $37,025 and $23,879 as of September 30, 2020 and December 31, 2019, respectively	381,888	459,751
Contract assets, net of allowance of $1,068 and $0 as of September 30, 2020 and December 31, 2019, respectively	101,333	95,982
Prepaid expenses and other current assets	135,869	147,990
Assets held for sale	104,782	0
Total current assets	948,782	841,262
Fixed assets, net	70,027	88,339
Software development costs, net	241,656	243,929
Intangible assets, net	329,011	374,142
Goodwill	1,287,197	1,362,017
Deferred taxes, net	5,881	5,704
Contract assets - long-term, net of allowance of $4,273 and $0 as of September 30, 2020 and December 31, 2019, respectively	42,805	67,559
Right-of-use assets - operating leases	102,217	98,020
Other assets	118,689	124,767
Total assets	3,146,265	3,205,739
Current liabilities:
Accounts payable	53,627	104,014
Accrued expenses	166,180	270,662
Accrued compensation and benefits	97,515	68,569
Deferred revenue	339,239	379,843
Current maturities of long-term debt	48,293	364,465
Current operating lease liabilities	22,317	23,137
Liabilities related to assets held for sale	17,479	0
Total current liabilities	744,650	1,210,690
Long-term debt	1,026,048	551,004
Deferred revenue	11,570	12,337
Deferred taxes, net	24,534	21,038
Long-term operating lease liabilities	98,866	95,162
Other liabilities	32,210	30,320
Total liabilities	1,937,878	1,920,551
Commitments and contingencies
Stockholders’ equity:
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of September 30, 2020 and December 31, 2019	0	0
Common stock: $0.01 par value, 349,000 shares authorized as of September 30, 2020 and December 31, 2019; 274,471 and 157,978 shares issued and outstanding as of September 30, 2020, respectively; 272,609 and 162,475 shares issued and outstanding as of December 31, 2019, respectively	2,744	2,725
Treasury stock: at cost, 116,493 and 110,134 shares as of September 30, 2020 and December 31, 2019, respectively	(625,246)	(571,157)
Additional paid-in capital	1,929,396	1,907,348
Accumulated deficit	(94,706)	(49,336)
Accumulated other comprehensive loss	(3,801)	(4,392)
Total stockholders’ equity	1,208,387	1,285,188
Total liabilities and stockholders’ equity	$ 3,146,265	$ 3,205,739

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Accounts receivable, allowance	$ 37,025	$ 23,879
Contract assets, allowance	1,068	0
Contract assets - long-term, allowance	$ 4,273	$ 0
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	349,000,000	349,000,000
Common stock, shares issued	274,471,000	272,609,000
Common stock, shares outstanding	157,978,000	162,475,000
Treasury stock at cost, shares	116,493,000	110,134,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue:
Revenue from contract with customers	$ 402,030	$ 444,184	$ 1,224,966	$ 1,320,693
Cost of revenue:
Amortization of software development and acquisition-related assets	33,207	29,295	95,860	86,547
Total cost of revenue	240,433	268,882	741,924	787,174
Gross profit	161,597	175,302	483,042	533,519
Selling, general and administrative expenses	97,231	101,152	309,139	306,939
Research and development	48,476	63,873	158,913	191,597
Asset impairment charges	210	248	210	4,037
Amortization of intangible and acquisition-related assets	6,301	6,847	19,347	20,376
Income (loss) from operations	9,379	3,182	(4,567)	10,570
Interest expense	(7,662)	(10,839)	(31,280)	(31,447)
Other income (loss), net	398	781	45	(143,700)
(Impairment) recovery of long-term investments	(1,025)	0	(1,575)	1,045
Equity in net income (loss) of unconsolidated investments	383	386	17,417	540
Income (loss) before income taxes	1,473	(6,490)	(19,960)	(162,992)
Income tax (provision) benefit	(931)	765	(7,457)	(640)
Net income (loss)	542	(5,725)	(27,417)	(163,632)
Net loss attributable to non-controlling interests	0	0	0	424
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ 542	$ (5,725)	$ (27,417)	$ (163,208)
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per share - Basic	$ 0	$ (0.03)	$ (0.17)	$ (0.97)
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per share - Diluted	$ 0	$ (0.03)	$ (0.17)	$ (0.97)
Software delivery, Support and Maintenance [Member]
Revenue:
Revenue from contract with customers	$ 250,547	$ 284,373	$ 770,180	$ 844,908
Cost of revenue:
Total cost of revenue	75,311	83,312	225,879	248,401
Client services [Member]
Revenue:
Revenue from contract with customers	151,483	159,811	454,786	475,785
Cost of revenue:
Total cost of revenue	$ 131,915	$ 156,275	$ 420,185	$ 452,226

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 542	$ (5,725)	$ (27,417)	$ (163,632)
Other comprehensive income (loss):
Foreign currency translation adjustments	983	(574)	(611)	(35)
Change in fair value of derivatives qualifying as cash flow hedges	1,009	(305)	1,620	(131)
Other comprehensive income (loss) before income tax (expense) benefit	1,992	(879)	1,009	(166)
Income tax (expense) benefit related to items in other comprehensive income (loss)	(260)	80	(418)	34
Total other comprehensive income (loss)	1,732	(799)	591	(132)
Comprehensive income (loss)	2,274	(6,524)	(26,826)	(163,764)
Comprehensive loss attributable to non-controlling interests	0	0	0	424
Comprehensive income (loss), net	$ 2,274	$ (6,524)	$ (26,826)	$ (163,340)

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock Issued [Member]	Treasury Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings (Accumulated Deficit) [Member]	Retained Earnings (Accumulated Deficit) [Member]Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Loss [Member]	Non-Controlling Interest [Member]
Beginning Balance, Shares at Dec. 31, 2018		270,955	(99,731)
Beginning Balance at Dec. 31, 2018	$ 1,580,427	$ 2,709	$ (460,543)	$ 1,881,494	$ 132,842	$ 0	$ (5,389)	$ 29,314
Stock-based compensation				29,296
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares		1,541
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 15		(6,702)
Capped call transactions				0
Issuance of treasury stock	701		$ 846	(144)
Issuance of treasury stock, Shares			61
Purchase of treasury stock, Shares			(9,607)
Purchase of treasury stock			$ (102,160)
Warrants issued				2,047
Acquisition of non-controlling interest				(29,913)				(28,890)
Net loss less net loss attributable to non-controlling interests	(163,208)
Foreign currency translation adjustments, net	(35)						(35)
Unrecognized gain (loss) on derivatives qualifying as cash flow hedges,net of tax	(97)
Net loss attributable to non-controlling interests	(424)							(424)
Ending Balance, Shares at Sep. 30, 2019		272,496	(109,277)
Ending Balance at Sep. 30, 2019	1,281,058	$ 2,724	$ (561,857)	1,876,078	(30,366)		(5,521)	0
Beginning Balance, Shares at Dec. 31, 2018		270,955	(99,731)
Beginning Balance at Dec. 31, 2018	$ 1,580,427	$ 2,709	$ (460,543)	1,881,494	132,842	0	(5,389)	29,314
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares	1,700
Ending Balance, Shares at Dec. 31, 2019	272,609	272,609	(110,134)
Ending Balance at Dec. 31, 2019	$ 1,285,188	$ 2,725	$ (571,157)	1,907,348	(49,336)	(17,953)	(4,392)	0
Beginning Balance, Shares at Jun. 30, 2019		272,472	(105,818)
Beginning Balance at Jun. 30, 2019	1,316,207	$ 2,724	$ (524,767)	1,867,613	(24,641)	0	(4,722)	0
Stock-based compensation				7,773
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares		24
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 0		9
Capped call transactions				0
Issuance of treasury stock			$ 0	0
Issuance of treasury stock, Shares			0
Purchase of treasury stock, Shares			(3,459)
Purchase of treasury stock			$ (37,090)
Warrants issued				683
Acquisition of non-controlling interest				0				0
Net loss less net loss attributable to non-controlling interests	(5,725)
Foreign currency translation adjustments, net	(574)						(574)
Unrecognized gain (loss) on derivatives qualifying as cash flow hedges,net of tax	(225)
Net loss attributable to non-controlling interests	0							0
Ending Balance, Shares at Sep. 30, 2019		272,496	(109,277)
Ending Balance at Sep. 30, 2019	$ 1,281,058	$ 2,724	$ (561,857)	1,876,078	(30,366)		(5,521)	0
Beginning Balance, Shares at Dec. 31, 2019	272,609	272,609	(110,134)
Beginning Balance at Dec. 31, 2019	$ 1,285,188	$ 2,725	$ (571,157)	1,907,348	(49,336)	(17,953)	(4,392)	0
Stock-based compensation				25,931
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares	1,900	1,862
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 19		(5,604)
Capped call transactions				797
Issuance of treasury stock	$ 752		$ 1,193	(440)
Issuance of treasury stock, Shares			90
Purchase of treasury stock, Shares			(6,449)
Purchase of treasury stock			$ (55,282)
Warrants issued				1,364
Acquisition of non-controlling interest				0				0
Net loss less net loss attributable to non-controlling interests	(27,417)
Foreign currency translation adjustments, net	(611)						(611)
Unrecognized gain (loss) on derivatives qualifying as cash flow hedges,net of tax	1,202
Net loss attributable to non-controlling interests	$ 0							0
Ending Balance, Shares at Sep. 30, 2020	274,471	274,471	(116,493)
Ending Balance at Sep. 30, 2020	$ 1,208,387	$ 2,744	$ (625,246)	1,929,396	(94,706)		(3,801)	0
Beginning Balance, Shares at Jun. 30, 2020		274,463	(111,493)
Beginning Balance at Jun. 30, 2020	1,242,929	$ 2,743	$ (579,678)	1,920,645	(95,248)	$ 0	(5,533)	0
Stock-based compensation				8,811
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares		8
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 1		(60)
Capped call transactions				0
Issuance of treasury stock			$ 0	0
Issuance of treasury stock, Shares			0
Purchase of treasury stock, Shares			(5,000)
Purchase of treasury stock			$ (45,568)
Warrants issued				0
Acquisition of non-controlling interest				0				0
Net loss less net loss attributable to non-controlling interests	$ 542
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201613Member
Foreign currency translation adjustments, net	$ 983						983
Unrecognized gain (loss) on derivatives qualifying as cash flow hedges,net of tax	749
Net loss attributable to non-controlling interests	$ 0							0
Ending Balance, Shares at Sep. 30, 2020	274,471	274,471	(116,493)
Ending Balance at Sep. 30, 2020	$ 1,208,387	$ 2,744	$ (625,246)	$ 1,929,396	$ (94,706)		$ (3,801)	$ 0

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net income (loss)	$ (27,417)	$ (163,632)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	153,682	152,250
Operating right-of-use asset amortization	16,149	16,722
Stock-based compensation expense	25,931	29,563
Deferred taxes	2,930	(3,066)
Asset impairment charges	210	4,037
Impairment (recovery) of long-term investments	1,575	(1,045)
Equity in net (income) loss of unconsolidated investments	(17,417)	(540)
Other (income) loss, net	(789)	2,796
Changes in operating assets and liabilities (net of businesses acquired):
Accounts receivable and contract assets, net	64,237	53,886
Prepaid expenses and other assets	4,289	615
Accounts payable	(49,611)	27,571
Accrued expenses	(3,564)	450
Accrued compensation and benefits	30,664	(43,426)
Deferred revenue	(26,820)	(138,639)
Other liabilities	1,710	(701)
Operating leases	(15,109)	(17,897)
Accrued DOJ settlement	(88,745)	145,000
Net cash provided by operating activities - continuing operations	71,905	63,944
Net cash used in operating activities - discontinued operations	0	(30,000)
Net cash provided by operating activities	71,905	33,944
Cash flows from investing activities:
Capital expenditures	(7,896)	(13,475)
Capitalized software	(78,032)	(86,190)
Cash paid for business acquisitions, net of cash acquired	0	(23,443)
Sales (purchases) of equity securities, other investments and related intangible assets, net	20,996	(7,191)
Other proceeds from investing activities	0	14
Net cash used in investing activities	(64,932)	(130,285)
Cash flows from financing activities:
Taxes paid related to net share settlement of equity awards	(5,589)	(6,762)
Repayment of Convertible Senior Notes	(352,361)	0
Payments for issuance costs on 0.875% Convertible Senior Notes	(758)	0
Credit facility payments	(175,000)	(15,000)
Credit facility borrowings, net of issuance costs	673,625	249,241
Repurchase of common stock	(55,282)	(102,160)
Repurchase of unsettled common stock	0	(9,301)
Payment of acquisition and other financing obligations	(4,369)	(11,581)
Purchases of subsidiary shares owned by non-controlling interest	0	(54,064)
Net cash provided by financing activities	80,266	50,373
Effect of exchange rate changes on cash and cash equivalents	132	(103)
Net increase (decrease) in cash and cash equivalents	87,371	(46,071)
Cash, cash equivalents and restricted cash, beginning of period	137,539	184,795
Cash, cash equivalents and restricted cash, end of period	$ 224,910	$ 138,724

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated. Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three and nine months ended September 30, 2020 and 2019 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting. The Company believes that the disclosures made are adequate to make these unaudited interim consolidated financial statements not misleading. They should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2019 (our “Form 10-K”). Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Our estimates and assumptions consider the economic implications of COVID-19 on our critical and significant accounting estimates. Actual results could differ materially from these estimates. Change in Presentation During the first quarter of 2020, we changed our reportable segments from Provider, Veradigm and Unallocated to Core Clinical and Financial Solutions, Data, Analytics and Care Coordination, and Unallocated. The business units reported within the historical segments have been reallocated into the new segments. Refer to Note 15 “Business Segments” for further discussion on the impact of the change. Certain reclassifications were made to prior period amounts in order to conform to the current period presentation. These reclassifications had no impact on the reported consolidated prior period financial results. Significant Accounting Policies We adopted Accounting Standards Update No. 2016-13, “ Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Recently Adopted Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2018-13, “Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” In March 2020, the FASB issued Accounting Standards Update No. 2020-04, “Reference Rate Reform (Topic 848) – Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”), which provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in ASU 2020-04 apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 will be effective for all entities as of March 12, 2020 through December 31, 2022. We adopted ASU 2020-04 on March 12, 2020, and the adoption had no impact on our consolidated financial statements. Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued Accounting Standards Update No. 2019-12, “ Income Taxes (Topic 740) In August 2020, the FASB issued Accounting Standards Update No. 2020-06, “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, will have a material impact on our consolidated financial statements.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	9 Months Ended
	Sep. 30, 2020
Revenue From Contract With Customer [Abstract]
Revenue from Contracts with Customers	2. Revenue from Contracts with Customers Our two primary revenue streams are (i) software delivery, support and maintenance and (ii) client services. Software delivery, support and maintenance revenue consists of all of our proprietary software sales (either under a perpetual or term license delivery model), subscription-based software sales, transaction-related revenue, the resale of hardware and third-party software and revenue from post-contract client support and maintenance services, which include telephone support services, maintaining and upgrading software and ongoing enhanced maintenance. Client services revenue consists of revenue from managed services solutions, such as private cloud hosting, outsourcing and revenue cycle management, as well as other client services and project-based revenue from implementation, training and consulting services. For some clients, we host the software applications licensed from us using our own or third-party servers. For other clients, we offer an outsourced service in which we assume partial to total responsibility for a healthcare organization’s IT operations using our employees. At September 30, 2020 and December 31, 2019, we had capitalized costs to obtain or fulfill a contract of $18.8 million and $20.8 million, respectively, in Prepaid and other current assets and $32.8 million and $32.9 million, respectively, in Other assets. During the three months ended September 30, 2020 and 2019, we recognized $6.8 million and $7.5 million, respectively, of amortization expense related to such capitalized costs. During the nine months ended September 30, 2020 and 2019, we recognized $20.9 million and $22.5 million, respectively, of amortization expense related to such capitalized costs. The amortization of these capitalized costs to obtain a contract are included in Selling, general and administrative expense within our consolidated statements of operations. The timing of revenue recognition, billings and cash collections results in billed and unbilled accounts receivable, contract assets and customer advances and deposits. Accounts receivable, net includes both billed and unbilled amounts where the right to receive payment is unconditional and only subject to the passage of time. Contract assets include amounts where revenue recognized exceeds the amount billed to the customer and the right to payment is not solely subject to the passage of time. Deferred revenue includes advanced payments and billings in excess of revenue recognized. Our contract assets and deferred revenue are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current or long-term based on the timing of when we expect to complete the related performance obligations and bill the customer. Deferred revenue is classified as current or long-term based on the timing of when we expect to recognize revenue. The breakdown of revenue recognized based on the origination of performance obligations and elected accounting expedients is presented in the table below: (In thousands) Three Months Ended March 31, 2020 Three Months Ended June 30, 2020 Three Months Ended September 30, 2020 Revenue related to deferred revenue balance at beginning of period $ 140,132 $ 155,616 $ 154,000 Revenue related to new performance obligations satisfied during the period 216,990 196,110 193,370 Revenue recognized under "right-to-invoice" expedient 58,059 54,082 54,313 Reimbursed travel expenses, shipping and other revenue 1,532 415 347 Total revenue $ 416,713 $ 406,223 $ 402,030 (In thousands) Three Months Ended March 31, 2019 Three Months Ended June 30, 2019 Three Months Ended September 30, 2019 Revenue related to deferred revenue balance at beginning of period $ 126,184 $ 146,150 $ 151,543 Revenue related to new performance obligations satisfied during the period 248,221 233,696 228,927 Revenue recognized under "right-to-invoice" expedient 55,923 62,245 61,814 Reimbursed travel expenses, shipping and other revenue 1,721 2,369 1,900 Total revenue $ 432,049 $ 444,460 $ 444,184 The aggregate amount of contract transaction price related to remaining unsatisfied performance obligations (commonly referred to as “backlog”) represents contracted revenue that has not yet been recognized and includes both deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. Total backlog equaled $4.4 billion as of September 30, 2020, of which we expect to recognize approximately 27% over the next 12 months, and the remaining 73% thereafter. Revenue Recognition We recognize revenue only when we satisfy an identified performance obligation (or bundle of obligations) by transferring control of a promised product or service to a customer. We consider a product or service to be transferred when a customer obtains control because a customer has sole possession of the right to use (or the right to direct the use of) the product or service for the remainder of its economic life or to consume the product or service in its own operations. We evaluate the transfer of control primarily from the customer’s perspective as this reduces the risk that revenue is recognized for activities that do not transfer control to the customer. The majority of our revenue is recognized over time because a customer continuously and simultaneously receives and consumes the benefits of our performance. The exceptions to this pattern are our sales of perpetual and term software licenses, and hardware, where we determined that a customer obtains control of the asset upon granting of access, delivery or shipment. We disaggregate our revenue from contracts with customers based on the type of revenue and nature of revenue stream, as we believe those categories best depict how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. The below tables summarize revenue by type and nature of revenue stream as well as by our reportable segments: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2020 2019 2020 2019 Revenue: Recurring revenue $ 333,900 $ 349,455 $ 1,010,207 $ 1,048,204 Non-recurring revenue 68,130 94,729 214,759 272,489 Total revenue $ 402,030 $ 444,184 $ 1,224,966 $ 1,320,693 Three Months Ended September 30, 2020 (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts Total Software delivery, support and maintenance $ 160,858 $ 85,231 $ 4,458 $ 250,547 Client services 145,593 3,603 2,287 151,483 Total revenue $ 306,451 $ 88,834 $ 6,745 $ 402,030 Three Months Ended September 30, 2019 (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts Total Software delivery, support and maintenance $ 191,280 $ 85,603 $ 7,490 $ 284,373 Client services 151,736 5,692 2,383 159,811 Total revenue $ 343,016 $ 91,295 $ 9,873 $ 444,184 Nine Months Ended September 30, 2020 (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts Total Software delivery, support and maintenance $ 502,159 $ 251,027 $ 16,994 $ 770,180 Client services 435,723 11,326 7,737 454,786 Total revenue $ 937,882 $ 262,353 $ 24,731 $ 1,224,966 Nine Months Ended September 30, 2019 (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts Total Software delivery, support and maintenance $ 574,715 $ 250,059 $ 20,134 $ 844,908 Client services 456,495 11,627 7,663 475,785 Total revenue $ 1,031,210 $ 261,686 $ 27,797 $ 1,320,693 Contract Assets – Estimate of Credit Losses We adopted ASU 2016-13 on January 1, 2020 using the cumulative-effect adjustment transition method. The new guidance required the recognition of lifetime estimated credit losses expected to occur for contract assets. The guidance also required that we pool assets with similar risk characteristics and consider current economic conditions when estimating losses. The adoption of ASU 2016-13 for contract assets was recorded as a debit to retained earnings of $5.3 million as of January 1, 2020. At adoption, we segmented the contract asset population into pools based on their risk assessment. Risks related to contract assets are a customer’s inability to pay or bankruptcy. Each pool was defined by their internal credit assessment, and business size. The pools are aligned with management’s review of financial performance. For the nine months ended September 30, 2020, no adjustment to the pools was necessary. We utilized a loss-rate method to measure expected credit loss for each pool. The loss rate is calculated using a twenty-four-month lookback period of credit memos and adjustments divided by the average contract asset balance for each pool during that period. We considered current economic conditions, including how the COVID-19 pandemic is impacting the global economy, internal forecasts, cash collection and credit memos written during the current period when assessing loss rates. We reviewed these factors and concluded that no adjustments should be made to the historical loss rate data. The September 30, 2020 analysis resulted in no change in the ending estimate of credit losses. Changes in the estimate of credit losses for contract assets are presented in the table below. (In thousands) Total Balance at January 1, 2020 $ 5,341 Current period provision 0 Balance at September 30, 2020 $ 5,341 Less: Contract assets, short-term 1,068 Total contract assets, long-term $ 4,273

Accounts Receivables

Accounts Receivables	9 Months Ended
	Sep. 30, 2020
Receivables [Abstract]
Accounts Receivables	3. Accounts Receivable Trade Accounts Receivable – Estimate of Credit Losses We adopted ASU 2016-13 on January 1, 2020 using the cumulative-effect adjustment transition method. The new guidance required the recognition of lifetime estimated credit losses expected to occur for trade accounts receivable. The guidance also required that we pool assets with similar risk characteristics and consider current economic conditions when estimating losses. The adoption of ASU 2016-13 for trade accounts receivable was recorded as a debit to retained earnings of $12.6 million as of January 1, 2020 At adoption, we segmented the accounts receivable population into pools based on their risk assessment. Risks related to trade accounts receivable are a customer’s inability to pay or bankruptcy. Each pool was defined by their internal credit assessment, and business size. The pools are aligned with management’s review of financial performance. For the nine months ended September 30, 2020, no adjustment to the pools was necessary. We utilized a loss-rate method to measure expected credit loss for each pool. The loss rate is calculated using a twelve-month lookback period of credit memos and adjustments divided by the average accounts receivable balance for each pool during that period. We considered current economic conditions, including how the COVID-19 pandemic is impacting the global economy, internal forecasts, cash collection and credit memos written during the current period when assessing loss rates. We reviewed these factors and concluded that no adjustments should be made to the historical loss rate data. Changes in the estimate of credit losses for trade accounts receivable are presented in the tables below. (In thousands) Total Balance at January 1, 2020 $ 36,490 Current period provision 9,164 Write-offs (8,286 ) Recoveries 73 Less: Reclassified allowance against receivables held for sale (1) (416 ) Balance at September 30, 2020 $ 37,025 (1 ) During the three months ended September 30, 2020, a portion of accounts receivable and the allowance thereon were reclassified to current assets held for sale in the accompanying consolidated balance sheets due to the Company’s entry into an asset purchase agreement with Strata Decision Technology LLC, to sell the EPSi TM TM

Leases

Leases	9 Months Ended
	Sep. 30, 2020
Lessee Disclosure [Abstract]
Leases	4. Leases We determine whether an arrangement is a lease at inception. Assets leased under an operating lease arrangement are recorded in Right-of-use assets – operating leases and the associated lease liabilities are included in Current operating lease liabilities and Long-term operating lease liabilities within the consolidated balance sheets. Assets leased under finance lease arrangements are recorded within fixed assets and the associated lease liabilities are recorded within Accrued expenses and Other liabilities within the consolidated balance sheets. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the expected lease term. Since our lease arrangements do not provide an implicit rate, we use our incremental borrowing rate in conjunction with the market swap rate for the expected remaining lease term at the commencement date for new leases in determining the present value of future lease payments. Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. We have elected the group of practical expedients under ASU 2016-02 to forego assessing upon adoption: (1) whether any expired contracts are or contain leases; (2) the lease classification for any existing or expired leases and (3) any indirect costs that would have qualified for capitalization for any existing leases. We have lease agreements with lease and non-lease components, which are generally accounted for separately except for real estate and vehicle leases, which we have elected to combine through a practical expedient under ASU 2016-02. Non-lease components for our leases typically consist of executory costs, and the practical expedient allows for all executory costs to be recorded as lease payments. Additionally, for certain equipment leases, we apply a portfolio approach to effectively record right-of-use assets and liabilities. Our operating leases mainly include office leases and our finance leases include office and computer equipment leases. Our finance leases are not significant. Our leases have remaining lease terms up to 8 years, some of which include options to extend the leases for up to 5 years, which may include options to terminate the leases within 1 year. Operating costs associated with leased assets are as follows: (In thousands) Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Operating lease cost (1) $ 6,430 $ 7,113 $ 19,791 $ 20,881 Less: Sublease income (257 ) (824 ) (1,026 ) (2,404 ) Total operating lease costs $ 6,173 $ 6,289 $ 18,765 $ 18,477 (1) Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statements of operations. Supplemental information for operating leases is as follows: (In thousands) Nine Months Ended September 30, 2020 2019 Operating cash flows from operating leases $ 21,082 $ 22,211 Right-of-use assets obtained in exchange for operating lease obligations $ 23,355 $ 144,080 The balance sheet location and balances for operating leases are as follows: (In thousands, except lease term and discount rate) September 30, 2020 December 31, 2019 Right-of-use assets - operating leases $ 102,217 $ 98,020 Current operating lease liabilities $ 22,317 $ 23,137 Long-term operating lease liabilities $ 98,866 $ 95,162 Weighted average remaining lease term (in years) 6 6 Weighted average discount rate 3.6 % 4.4 % The future maturities of our leasing arrangements including lease and non-lease components are shown in the below table. The maturities are calculated using foreign currency exchange rates in effect as of September 30, 2020. September 30, 2020 (In thousands) Operating Leases Remainder of 2020 $ 6,593 2021 26,763 2022 25,068 2023 22,856 2024 17,267 Thereafter 36,667 Total lease liabilities 135,214 Less: Amount representing interest (13,059 ) Less: Reclassified lease liabilities held for sale (1) (972 ) Less: Short-term lease liabilities (22,317 ) Total long-term lease liabilities $ 98,866 (1) TM TM

Business Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2020
Business Combinations [Abstract]
Business Combinations	5. Business Combinations Acquisitions On July 2, 2019, we acquired the Pinnacle and Diabetes Collaborative Registries from the American College of Cardiology (“ACC”) as part of our broader strategic partnership with the ACC. The total purchase price was $19.7 million, consisting of an initial payment of $11.7 million plus up to an aggregate of $8.0 million pending the attainment certain milestones over the next 18 months. The contingent consideration of up to $8.0 million was valued at $5.0 million at the time of closing. As part of this partnership, we operate Pinnacle and Diabetes Collaborative Registries, which extends our EHR-enabled ambulatory network to create a large-scale chronic disease network. The business is included in our Data, Analytics and Care Coordination business segment. On June 10, 2019, we acquired the assets of a business engaged in the development, implementation, customization, marketing, licensing and sale of a specialty prescription drug platform, including software that collects, saves and transmits information required to fill a prescription. The drug platform and software enables healthcare providers, pharmacists and payors to digitally interact with one another to fill a prescription. The business is included in our Data, Analytics and Care Coordination business segment. On March 1, 2019, we acquired all of the outstanding minority interests in Pulse8, Inc., a healthcare analytics and technology company that provides business intelligence software solutions for health plans and at-risk providers to enable them to analyze their risk adjustment and quality management programs, for $53.8 million (subject to adjustments for net working capital and a contingency holdback). We initially acquired a controlling stake in Pulse 8, Inc. on September 8, 2016. This transaction was treated as an equity transaction, and the cash payment is reported as part of cash flow from financing activities in the consolidated statement of cash flows for the nine months ended September 30, 2019. Divestitures On July 30, 2020, we signed an asset purchase agreement with Strata Decision Technology LLC, an Illinois limited liability company (“Strata”), and Roper Technologies, Inc., a Delaware corporation (the “EPSi Purchase Agreement”), pursuant to which Strata agreed to purchase substantially all of assets of our TM applicable waiting period (and any extensions thereof) under Hart-Scott-Rodino Antitrust Improvements Act having expired or otherwise having been terminated. As of September 30, 2020, the assets and liabilities related to the EPSi Purchase Agreement were classified as held-for-sale on our consolidated balance sheet. The held-for-sale assets and liabilities are classified as current since we expect to complete the sale of the disposal group within the next 12 months. The business classified as held-for-sale was classified in continuing operations as the disposition does not represent a strategic shift that will have a major effect on our operations and financial results. On October 15, 2020, we completed the sale of the TM The following table provides the components of those assets and liabilities related to the EPSi Purchase Agreement which are classified as held-for-sale as of September 30, 2020: (In thousands) September 30, 2020 Assets held for sale: Current assets: Accounts receivable, net of allowance of $416 $ 10,088 Contract assets 4,147 Prepaid expenses and other current assets 956 Total current assets classified as held for sale 15,191 Fixed assets, net 254 Software development costs, net 10,977 Goodwill 74,663 Contract assets - long-term 2,765 Right-of-use assets - operating leases 932 Total assets held for sale $ 104,782 Liabilities related to assets held for sale: Current liabilities: Accrued expenses $ 964 Accrued compensation and benefits 1,714 Deferred revenue 13,400 Current operating lease liabilities 371 Total current liabilities classified as held for sale 16,449 Deferred revenue 429 Long-term operating lease liabilities 601 Total liabilities related to assets held for sale $ 17,479

Fair Value Measurements and Lon

Fair Value Measurements and Long-term Investments	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements and Long-term Investments	6. Fair Value Measurements and Long-term Investments Fair value measurements are based upon observable and unobservable inputs. Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2: Quoted prices for similar instruments in active markets with inputs that are observable, either directly or indirectly. Our Level 2 derivative financial instruments include foreign currency forward contracts valued based upon observable values of spot and forward foreign currency exchange rates. Level 3: Unobservable inputs are significant to the fair value of the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 instruments include the fair value of contingent consideration related to completed acquisitions. The fair values are based on discounted cash flow analyses reflecting the likelihood of achieving specified performance measures or events and captures the contractual nature of the contingencies, commercial risk or time value of money. Level 3 instruments also included the 1.25% Call Option asset and the 1.25% embedded cash conversion option liability that are not actively traded. The changes in unobservable inputs to the valuation pricing model used to value these instruments is not material to our consolidated results of operations. On July 1, 2020, these instruments matured and were repaid in full. The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet September 30, 2020 December 31, 2019 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Foreign exchange derivative assets Prepaid expenses and other current assets $ 0 $ 1,620 $ 0 $ 1,620 $ 0 $ 0 $ 0 $ 0 1.25% Call Option Other assets 0 0 0 0 0 0 84 84 Total assets $ 0 $ 1,620 $ 0 $ 1,620 $ 0 $ 0 $ 84 $ 84 Contingent consideration - current Accrued expenses $ 0 $ 0 $ 16,115 $ 16,115 $ 0 $ 0 $ 17,116 $ 17,116 Contingent consideration - long-term Other liabilities 0 0 0 0 0 0 2,415 2,415 1.25% Embedded cash conversion option Other liabilities 0 0 0 0 0 0 185 185 Total liabilities $ 0 $ 0 $ 16,115 $ 16,115 $ 0 $ 0 $ 19,716 $ 19,716 The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at September 30, 2020 are summarized as follows: (In thousands) Contingent Consideration 1.25% Notes Call Spread Overlay Balance at December 31, 2019 $ 19,531 $ (101 ) Additions 773 0 Payments (4,189 ) 0 Fair value adjustments 0 101 Balance at September 30, 2020 $ 16,115 $ 0 The following table summarizes the quantitative information about our Level 3 fair value measurements at September 30, 2020: September 30, 2020 (In thousands, except the discount rate) Fair Value Valuation Technique Significant Unobservable Inputs Ranges of Inputs Weighted Average (1) Financial instruments: Contingent consideration $ 16,115 Probability Weighted Discounted cash flow Discount rate 4% to 5% 4 % Revenue $0 to $62,500 $ 31,250 Registry members 0 to 1,551 776 Patient data volume 0 to 52,845 26,422 Projected year of payment 2020 to 2021 Total financial instruments $ 16,115 (1) The weighted average is calculated based upon the absolute fair value of the instruments. Long-term Investments The following table summarizes our long-term equity investments which are included in Other assets in the accompanying consolidated balance sheets: Number of Investees Original Carrying Value at (In thousands, except for number of investees) at September 30, 2020 Cost September 30, 2020 December 31, 2019 Equity method investments (1) 3 $ 7,099 $ 11,051 $ 11,332 Cost less impairment 8 37,568 24,995 32,462 Total long-term equity investments 11 $ 44,667 $ 36,046 $ 43,794 (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag. During the nine months ended September 30, 2020, we recorded a $16.8 million gain from the sale of a third-party equity method investment, which occurred in the second quarter of 2020. As of September 30, 2020, it is not possible to estimate the fair value of our non-marketable cost and equity method investments, primarily because of their illiquidity and restricted marketability. The factors we considered in trying to determine fair value include, but are not limited to, available financial information, the issuer’s ability to meet its current obligations, the issuer’s subsequent or planned raises of capital and observable price changes in orderly transactions. Impairment and Recovery of Long-term Investments During the three and nine months ended September 30, 2020, we recorded non-cash impairment charges of $1.0 million and $1.6 million, respectively, related to our long-term investments. Each quarter, management performs an assessment of each of our investments on an individual basis to determine if there have been any declines in fair value. Based on our review in the third quarter of 2020, we determined to recognize an impairment charge related to one of our cost-method investments, which equaled the cost basis of our initial investment. In the second quarter of 2020, we reached a settlement agreement with one of our third-party equity-method investments, which resulted in the recognition of a $0.6 million impairment charge. During the nine months ended September 30, 2019, we recovered $1.0 million from a third-party cost-method investment that we had previously impaired. The impairment charges and the amount recovered are recognized in the (Impairment) recovery of long-term investments in the consolidated statements of operations. Long-term Financial Liabilities Our long-term financial liabilities include amounts outstanding under our senior secured credit facility (as described in Note 10, “Debt”), with carrying values that approximate fair value since the interest rates approximate current market rates. As of December 31, 2019, the carrying amount of our 1.25% Cash Convertible Senior Notes (the “1.25% Notes”) approximated fair value since the effective interest rate on the 1.25% Notes approximated current market rates. On July 1, 2020, the 1.25% Notes matured and were paid in full. Refer to Note 10, “Debt,” for further information regarding our long-term financial liabilities.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Stockholders' Equity	7. Stockholders' Equity Stock-based Compensation Expense Stock-based compensation expense recognized during the three and nine months ended September 30, 2020 and 2019 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. No stock-based compensation costs were capitalized during the three and nine months ended September 30, 2020 and 2019. Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2020 2019 2020 2019 Cost of revenue: Software delivery, support and maintenance $ 295 $ 395 $ 1,213 $ 1,522 Client services 1,519 765 3,418 3,021 Total cost of revenue 1,814 1,160 4,631 4,543 Selling, general and administrative expenses 6,728 5,643 18,851 20,799 Research and development 2,127 1,677 5,950 7,125 Total stock-based compensation expense $ 10,669 $ 8,480 $ 29,432 $ 32,467 Allscripts Long-Term Incentive Plan We measure stock-based compensation expense at the grant date based on the fair value of the award. We recognize the expense for service-based share awards over the requisite service period on a straight-line basis, net of estimated forfeitures. We recognize the expense for performance-based and market-based share awards over the vesting period under the accelerated attribution method, net of estimated forfeitures. In addition, we recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved. The fair value of service-based and performance-based restricted stock units is measured at the underlying closing share price of our common stock on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. No stock options were granted during the three and nine months ended September 30, 2020 and 2019. We granted stock-based awards as follows: Three Months Ended September 30, 2020 Nine Months Ended September 30, 2020 Weighted-Average Weighted-Average Grant Date Grant Date (In thousands, except per share amounts) Shares Fair Value Shares Fair Value Service-based restricted stock units 90 $ 8.90 4,508 $ 6.44 Performance-based restricted stock units with a service condition 504 $ 7.19 504 $ 7.19 Market-based restricted stock units with a service condition 0 $ 0.00 595 $ 9.98 594 $ 7.45 5,607 $ 6.88 During the nine months ended September 30, 2020 and the year ended December 31, 2019, 1.9 million and 1.7 million shares of common stock, respectively, were issued in connection with the exercise of options and the release of restrictions on stock awards. Net Share-settlements Upon vesting, restricted stock units are generally net share-settled to cover the required withholding tax, and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested during the nine months ended September 30, 2020 and 2019 were net-share settled such that we withheld shares with fair value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes and remitted the cash to the appropriate taxing authorities. Total payments for the employees' minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld for the nine months ended September 30, 2020 and 2019 were 770 thousand and 658 thousand, respectively, and were based on the value of the restricted stock units on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting. Stock Repurchases On August 2, 2018, we announced that our Board of Directors approved a stock purchase program (the “2018 Program”) under which we may repurchase up to $250 million of our common stock through December 31, 2020. We repurchased 5.0 million shares of our common stock under the 2018 Program for a total of $45.6 million during the three months ended September 30, 2020. We repurchased 6.5 million shares of our common stock under the 2018 Program for a total of $55.3 million during the nine months ended September 30, 2020. The approximate dollar value of shares that may yet be purchased under the 2018 Program is $46.6 million as of September 30, 2020. We repurchased 3.5 million shares of our common stock under the 2018 Program for a total of $37.1 million during the three months ended September 30, 2019. We repurchased 9.6 million shares of our common stock under the 2018 Program for a total of $102.2 million during the nine months ended September 30, 2019. We did initiate share transactions to purchase an additional 0.9 million shares for $9.3 million under the 2018 Program for the three months ended September 30, 2019, but the transactions were not settled until October 2019. The shares settled in October 2019 were outstanding as of September 30, 2019, and therefore were recorded as a financing transaction as “Repurchase of unsettled common stock” within the consolidated statements of cash flows and recorded as “Other assets” within the consolidated balance sheets. Any future stock repurchase transactions may be made through open market transactions, block trades, privately negotiated transactions (including accelerated share repurchase transactions) or other means, subject to market conditions. Any repurchase activity will depend on many factors such as our working capital needs, cash requirements for investments, debt repayment obligations, economic and market conditions at the time, including the price of our common stock, and other factors that we consider relevant. Our stock repurchase program may be accelerated, suspended, delayed or discontinued at any time.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	8. Earnings (Loss) Per Share Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings (loss) per share, the denominator includes both the weighted-average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of stock options, restricted stock unit awards and warrants calculated under the treasury stock method. The calculations of earnings (loss) per share are as follows: Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except per share amounts) 2020 2019 2020 2019 Basic earnings (loss) per Common Share: Net income (loss) $ 542 $ (5,725 ) $ (27,417 ) $ (163,632 ) Net loss attributable to non-controlling interests 0 0 0 424 Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders $ 542 $ (5,725 ) $ (27,417 ) $ (163,208 ) Weighted-average common shares outstanding 161,144 166,391 162,092 167,610 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share $ 0.00 $ (0.03 ) $ (0.17 ) $ (0.97 ) Diluted earnings (loss) per Common Share: Net income (loss) $ 542 $ (5,725 ) $ (27,417 ) $ (163,632 ) Net loss attributable to non-controlling interests 0 0 0 424 Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders $ 542 $ (5,725 ) $ (27,417 ) $ (163,208 ) Weighted-average common shares outstanding 161,144 166,391 162,092 167,610 Plus: Dilutive effect of stock options, restricted stock unit awards and warrants 2,168 0 0 0 Weighted-average common shares outstanding assuming dilution 163,312 166,391 162,092 167,610 Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share $ 0.00 $ (0.03 ) $ (0.17 ) $ (0.97 ) Due to the net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders for the nine months ended September 30, 2020 and the three and nine months ended September 30, 2019, we used basic weighted-average common shares outstanding in the calculation of diluted loss per share for those periods, since the inclusion of any stock equivalents would be anti-dilutive. The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2020 2019 2020 2019 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 47,162 27,969 48,816 27,350

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	9. Goodwill and Intangible Assets Goodwill and intangible assets consist of the following: September 30, 2020 December 31, 2019 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 546,289 $ (463,298 ) $ 82,991 $ 546,373 $ (437,640 ) $ 108,733 Customer contracts and relationships 701,976 (507,956 ) 194,020 702,034 (488,625 ) 213,409 Total $ 1,248,265 $ (971,254 ) $ 277,011 $ 1,248,407 $ (926,265 ) $ 322,142 Intangibles not subject to amortization: Registered trademarks $ 52,000 $ 52,000 Goodwill 1,287,197 1,362,017 Total $ 1,339,197 $ 1,414,017 Changes in the carrying amounts of goodwill by reportable segment for the nine months ended September 30, 2020 were as follows: (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts (2) Total Balance as of December 31, 2019 734,883 552,471 74,663 1,362,017 Foreign exchange translation (157 ) 0 0 (157 ) Reclassification to assets held for sale (1) 0 0 (74,663 ) (74,663 ) Balance as of September 30, 2020 $ 734,726 $ 552,471 $ 0 $ 1,287,197 (1) During the three months ended September 30, 2020, the carrying amount of goodwill assigned to the EPSi TM TM TM ( 2 ) The EPSi TM There are $39.2 million in accumulated impairment losses associated with our goodwill as of September 30, 2020 and December 31, 2019.

Debt

Debt	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Debt	10. Debt Debt outstanding, excluding lease obligations, consists of the following: September 30, 2020 December 31, 2019 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 0.875% Convertible Senior Notes (1) $ 167,853 $ (1,712 ) $ 169,565 $ 177,942 $ 4,697 $ 173,245 1.25% Cash Convertible Senior Notes 0 0 0 345,000 7,552 337,448 Senior Secured Credit Facility 910,000 5,224 904,776 410,000 5,224 404,776 Total debt $ 1,077,853 $ 3,512 $ 1,074,341 $ 932,942 $ 17,473 $ 915,469 Less: Debt payable within one year 49,000 707 48,293 364,653 188 364,465 Total long-term debt, less current maturities $ 1,028,853 $ 2,805 $ 1,026,048 $ 568,289 $ 17,285 $ 551,004 (1) Principal balance is $207,911 thousand; $167,853 thousand is recognized in debt and $40,058 thousand is recognized in additional paid-in capital Interest expense consists of the following: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2020 2019 2020 2019 Interest expense $ 5,646 $ 6,741 $ 17,833 $ 19,404 Amortization of discounts and debt issuance costs 2,016 4,098 13,447 12,043 Total interest expense $ 7,662 $ 10,839 $ 31,280 $ 31,447 Interest expense related to the 0.875% Convertible Senior Notes and the 1.25% Cash Convertible Senior Notes, included in the table above, consisted of the following: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2020 2019 2020 2019 Coupon interest $ 451 $ 1,078 $ 3,561 $ 3,234 Amortization of discounts and debt issuance costs 1,454 3,685 12,030 10,876 Total interest expense related to the convertible notes $ 1,905 $ 4,763 $ 15,591 $ 14,110 Allscripts Senior Secured Credit Facility On February 15, 2018, Allscripts and Healthcare LLC entered into a Second Amended and Restated Credit Agreement (the “Second Amended Credit Agreement”), with JPMorgan Chase Bank, N.A., as administrative agent. The Second Amended Credit Agreement provides for a $400 million senior secured term loan (the “Term Loan”) and a $900 million senior secured revolving facility (the “Revolving Facility”), each with a five-year term. The Term Loan is repayable in quarterly installments, which began on June 30, 2018. A total of up to $ 50 million of the Revolving Facility is available for the issuance of letters of credit, up to $10 million of the Revolving Facility is available for swingline loans, and up to $ 100 million of the Revolving Facility could be borrowed under certain foreign currencies. As of September 30, 2020, $310.0 million under the Term Loan, $600.0 million under the Revolving Facility, and $1.1 million in letters of credit were outstanding under the Second Amended Credit Agreement. As of September 30, 2020, the interest rate on the borrowings under the Second Amended Credit Agreement was LIBOR plus 2.00%, which totaled 2.15%. We were in compliance with all covenants under the Second Amended Credit Agreement as of September 30, 2020. In connection with the sale of our EPSi TM which is further discussed in Note 17, “Subsequent Events”, the terms of our Second Amended and Restated Credit Agreement required us to make a mandatory prepayment of our Term Loan in the amount of $19.0 million on October 29, 2020, which is therefore included in current maturities of long-term debt at September 30, 2020. On August 7, 2019, we entered into a First Amendment to the Second Amended Credit Agreement in order to remain compliant with the covenants of our Second Amended Credit Agreement. The First Amendment provided the financial flexibility to settle the U.S. Department of Justice’s investigations as discussed in Note 14, “Contingencies” while maintaining our compliance with the covenants of our Second Amended Credit Agreement. None of the original terms of our Second Amended Credit Agreement relating to scheduled future principal payments, applicable interest rates and margins or borrowing capacity under our Revolving Facility were amended. In connection with this amendment, we incurred fees and other costs totaling $0.8 million, of which a majority was capitalized. On July 20, 2020, we entered into a Second Amendment to the Second Amended Credit Agreement. None of the original terms of our Second Amended Credit Agreement relating to scheduled future principal payments, applicable interest rates and margins or borrowing capacity under our Revolving Facility were amended. In connection with this amendment, we incurred fees and other costs totaling $1.4 million, of which a majority was capitalized. As of September 30, 2020, we had $298.9 million available, net of outstanding letters of credit, under our Revolving Facility. There can be no assurance that we will be able to draw on the full available balance of our Revolving Facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings or if we are unable to maintain compliance with applicable covenants. 0.875% Convertible Senior Notes The issuance in December 2019 of the combined $ 218.0 0.7 million in debt issuance costs, which were paid in January 2020. We have separately recorded liability and equity components of the 0.875% Convertible Senior Notes, including any discounts and issuance costs, by allocating the proceeds from the issuance between the liability component and the embedded conversion option, or equity component. This allocation was completed by first estimating an interest rate at the time of issuance for similar notes that do not include an embedded conversion option. The semi-annual interest rate of 1.95 % was used to compute the initial fair value of the liability component, which totaled $ 177.9 time of issuance. The excess of the initial proceeds received from the 0.875% Convertible Senior Notes and the $177.9 million liability component was allocated to the equity component, which totaled $ 40.1 17.2 1.1 1.25% Cash Convertible Senior Notes On July 1, 2020, the 1.25% Cash Convertible Senior Notes matured and were repaid utilizing $345.0 million drawn against the Revolving Facility. The following table summarizes future debt payment obligations as of September 30, 2020: (In thousands) Total Remainder of 2020 2021 2022 2023 2024 Thereafter 0.875% Convertible Senior Notes (1) $ 207,911 $ 0 $ 0 $ 0 $ 0 $ 0 $ 207,911 Term Loan 310,000 26,500 30,000 37,500 216,000 0 0 Revolving Facility (2) 600,000 0 0 0 600,000 0 0 Total debt $ 1,117,911 $ 26,500 $ 30,000 $ 37,500 $ 816,000 $ 0 $ 207,911 (1) Amount represents face value of the 0.875% Convertible Senior Notes, which includes both the liability and equity portion. ( 2 ) Assumes no additional borrowings after September 30, 2020, payment of any required periodic installments of principal and that all drawn amounts are repaid upon maturity.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes We account for income taxes under FASB Accounting Standards Codification 740, “ Income Taxes” Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except effective tax rate) 2020 2019 2020 2019 Income (loss) before income taxes $ 1,473 $ (6,490 ) $ (19,960 ) $ (162,992 ) Income tax (provision) benefit $ (931 ) $ 765 $ (7,457 ) $ (640 ) Effective tax rate 63.2 % 11.8 % (37.4 %) (0.4 %) Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate primarily due to permanent differences, income attributable to foreign jurisdictions taxed at different rates, state taxes, tax credits and certain discrete items. Our effective tax rate for the three and nine months ended September 30, 2020, compared with the prior year comparable periods, differs primarily due to the fact that the permanent items, credits and the impact of foreign earnings had less impact on the pre-tax income (loss) of $1.5 million and ($20.0) million in the three and nine months ended September 30, 2020, respectively, compared to the impacts of these items on a pre-tax loss of $6.5 million and $163.0 million for the three and nine months ended September 30, 2019, respectively. In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). During the nine months ended September 30, 2020, we recorded valuation allowances of $1.2 million related to U.S. and foreign net operating loss carryforwards. Our unrecognized income tax benefits were $21.4 million and $20.6 million as of September 30, 2020 and December 31, 2019, respectively. If any portion of our unrecognized tax benefits is recognized, it could impact our effective tax rate. The tax reserves are reviewed periodically and adjusted considering changing facts and circumstances, such as progress of tax audits, lapse of applicable statutes of limitations and changes in tax law.

Derivative Financial Instrument

Derivative Financial Instruments	9 Months Ended
	Sep. 30, 2020
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	12. Derivative Financial Instruments The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: September 30, 2020 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 1,620 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 0 N/A 1.25% Embedded cash conversion option N/A Other liabilities 0 Total derivatives $ 1,620 $ 0 December 31, 2019 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 0 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 84 N/A 1.25% Embedded cash conversion option N/A Other liabilities 185 Total derivatives $ 84 $ 185 N/A – We define “N/A” as disclosure not being applicable Foreign Exchange Contracts We have entered into non-deliverable forward foreign currency exchange contracts with reputable banking counterparties to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR. These forward contracts cover a percentage of forecasted monthly INR expenses over time. As of September 30, 2020, there were nine forward contracts outstanding that were staggered to mature monthly starting in October 2020 June 2021 The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss: Amount of Gain (Loss) Recognized in OCI Amount of Gain (Loss) Reclassified from AOCI into Income (In thousands) Three Months Ended September 30, 2020 Nine Months Ended September 30, 2020 Location of Gain (Loss) Reclassified from AOCI into Income Three Months Ended September 30, 2020 Nine Months Ended September 30, 2020 Foreign exchange contracts $ 1,280 $ 1,798 Cost of Revenue $ 107 $ 71 Selling, general and administrative expenses 52 34 Research and development $ 111 $ 73 Amount of Gain (Loss) Recognized in OCI Amount of Gain (Loss) Reclassified from AOCI into Income (In thousands) Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 Location of Gain (Loss) Reclassified from AOCI into Income Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 Foreign exchange contracts $ (257 ) $ 83 Cost of Revenue $ 16 $ 76 Selling, general and administrative expenses 12 53 Research and development $ 19 $ 85 1.25% Call Option In June 2013, concurrent with the issuance of the 1.25% Notes, we entered into privately negotiated hedge transactions with certain of the initial purchasers of the 1.25% Notes (collectively, the “1.25% Call Option”). Assuming full performance by the counterparties, the 1.25% Call Option was intended to offset cash payments in excess of the principal amount due upon any conversion of the 1.25% Notes. On July 1, 2020, the 1.25% Notes matured and were repaid in full (refer to Note 10 “Debt”) and the 1.25% Call Option expired. Prior to its expiration, the 1.25% Call Option was measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. The 1.25% Call Option did not qualify for hedge accounting treatment. Therefore, the change in fair value of these instruments was recognized immediately in our consolidated statements of operations in Other income, net. Because the terms of the 1.25% Call Option are substantially similar to those of the 1.25% Notes embedded cash conversion option, discussed below, the net effect of those two derivative instruments on our earnings was minimal. 1.25% Notes Embedded Cash Conversion Option The embedded cash conversion option within the 1.25% Notes was required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations in Other income, net until the cash conversion option settles or expires. The cash conversion option expired without ever having required settlement prior to the maturity of the 1.25% Notes. The initial fair value liability of the embedded cash conversion option was $82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). The embedded cash conversion option was measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes’ embedded cash conversion option in the consolidated statements of operations: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2020 2019 2020 2019 1.25% Call Option $ 0 $ (3,567 ) $ (84 ) $ (6,262 ) 1.25% Embedded cash conversion option 0 3,746 185 6,355 Net income included in Other income, net $ 0 $ 179 $ 101 $ 93

Other Comprehensive Income

Other Comprehensive Income	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Other Comprehensive Income	13. Other Comprehensive Income Accumulated Other Comprehensive Loss Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2019 (1) $ (4,392 ) $ 0 $ (4,392 ) Other comprehensive loss (income) before reclassifications (611 ) 1,334 723 Net losses (gains) reclassified from accumulated other comprehensive loss 0 (132 ) (132 ) Net other comprehensive (loss) income (611 ) 1,202 591 Balance as of September 30, 2020 (2) $ (5,003 ) $ 1,202 $ (3,801 ) (1) (2) (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2018 (1) $ (5,584 ) $ 195 $ (5,389 ) Other comprehensive income (loss) before reclassifications (35 ) 61 26 Net (gains) losses reclassified from accumulated other comprehensive loss 0 (158 ) (158 ) Net other comprehensive income (35 ) (97 ) (132 ) Balance as of September 30, 2019 (2) $ (5,619 ) $ 98 $ (5,521 ) (1) (2) Income Tax Effects Related to Components of Other Comprehensive Income (Loss) The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended September 30, 2020 2019 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 983 $ 0 $ 983 $ (574 ) $ 0 $ (574 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 1,280 (330 ) 950 (257 ) 67 (190 ) Net losses (gains) reclassified into income (271 ) 70 (201 ) (48 ) 13 (35 ) Net change in unrealized gains (losses) on foreign exchange contracts 1,009 (260 ) 749 (305 ) 80 (225 ) Net gain (loss) on cash flow hedges 1,009 (260 ) 749 (305 ) 80 (225 ) Other comprehensive income (loss) $ 1,992 $ (260 ) $ 1,732 $ (879 ) $ 80 $ (799 ) Nine Months Ended September 30, 2020 2019 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ (611 ) $ 0 $ (611 ) $ (35 ) $ 0 $ (35 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 1,798 (464 ) 1,334 83 (22 ) 61 Net losses (gains) reclassified into income (178 ) 46 (132 ) (214 ) 56 (158 ) Net change in unrealized gains (losses) on foreign exchange contracts 1,620 (418 ) 1,202 (131 ) 34 (97 ) Net gain (loss) on cash flow hedges 1,620 (418 ) 1,202 (131 ) 34 (97 ) Other comprehensive (loss) income $ 1,009 $ (418 ) $ 591 $ (166 ) $ 34 $ (132 )

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Contingencies	14. Contingencies In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated. We intend to vigorously defend ourselves, as appropriate, in these matters. No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. In the opinion of our management, except as set forth below with respected to the resolution of the Practice Fusion investigations, the ultimate disposition of pending legal proceedings or claims will not have a material adverse effect on our consolidated financial position, liquidity or results of operations. However, if one or more of these additional legal proceedings were resolved against or settled by us in a reporting period for amounts in excess of our management’s expectations, our consolidated financial statements for that and subsequent reporting periods could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients or cause us to incur increased compliance costs, either of which could further adversely affect our operating results. The Enterprise Information Solutions business (the “EIS Business”) acquired from McKesson Corporation (“McKesson”) on October 2, 2017 is subject to a May 2017 civil investigative demand (“CID”) from the U.S. Attorney’s Office for the Eastern District of New York. The CID requests documents and information related to the certification McKesson obtained for Horizon Clinicals in connection with the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program. In August 2018, McKesson received an additional CID seeking similar information for Paragon. McKesson has agreed, with respect to the CIDs, to indemnify Allscripts for amounts paid or payable to the government (or any private relator) involving any products or services marketed, sold or licensed by the EIS Business as of or prior to the closing of the acquisition. Practice Fusion, acquired by Allscripts on February 13, 2018, received in March 2017 a request for documents and information from the U.S. Attorney’s Office for the District of Vermont pursuant to a CID. Between April 2018 and June 2019, Practice Fusion received from the U.S. Department of Justice (the “DOJ”) seven additional requests for documents and information through four additional CIDs and three Health Insurance Portability and Accountability Act (“HIPAA”) subpoenas. The document and information requests received by Practice Fusion related to both the certification Practice Fusion obtained in connection with the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program and Practice Fusion’s compliance with the Anti-Kickback Statute (“AKS”) and HIPAA as it relates to certain business practices engaged in by Practice Fusion. In March 2019, Practice Fusion received a grand jury subpoena in connection with a criminal investigation related to Practice Fusion’s compliance with the AKS. On August 6, 2019, Practice Fusion reached an agreement in principle with the DOJ to resolve all of the DOJ’s outstanding civil and criminal investigations, including the investigation by the U.S. Attorney’s Office for the District of Vermont, and we announced that on January 27, 2020, Practice Fusion entered into a deferred prosecution agreement and various civil settlement agreements, including with the Medicaid programs for each U.S. state, the District of Columbia and Puerto Rico (collectively, the “Settlement Agreements”) resolving the investigations conducted by the DOJ and the U.S. Attorney’s Office. The Settlement Agreements require Practice Fusion to, among other matters, pay a criminal fine of $25.3 million, a forfeiture payment of $959,700 and a civil settlement of $118.6 million, which includes $5.2 million designated for the state Medicaid program expenditures. The terms of Settlement Agreements resolved, among other things, allegations that Practice Fusion, long before its acquisition by Allscripts and concerning conduct about which Allscripts was unaware at the time of the acquisition, violated the AKS through the manner by which a sponsored Clinical Decision Support arrangement was sold to an opioid manufacturer and other AKS allegations made by the DOJ against Practice Fusion, as well as False Claims Act allegations pertaining to Meaningful Use payments the federal government made to users of Practice Fusion’s EHR system. In April 2020, Practice Fusion amended its civil settlement agreement with the DOJ by revising the timing of certain of the payments required to be made by Practice Fusion. Pursuant to the amendment, the Federal settlement amounts that were otherwise owed in the Company’s second and third fiscal quarters were reduced by half, and the balance of the Federal settlement amount owed by Practice Fusion will become due in January 2021.

Business Segments

Business Segments	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Business Segments	15. Business Segments We primarily derive our revenues from sales of our proprietary software (either as a direct license sale or under a subscription delivery model), which also serves as the basis for our recurring service contracts for software support and maintenance and certain transaction-related services. In addition, we provide various other client services, including installation, and managed services such as outsourcing, private cloud hosting and revenue cycle management. During the first quarter of 2020, we realigned our reporting structure to organize the Company around strategic business units to maximize delivery of client commitments, operational effectiveness and competitiveness. As a result, we have three operating segments, (i) Core Clinical and Financial Solutions, (ii) Data, Analytics and Care Coordination and (iii) EPSi TM During the second quarter of 2020, (i) certain operations were moved between Core Clinical and Financial Solutions, and Data, Analytics and Care Coordination and (ii) a transfer price allocation was recorded between Core Clinical and Financial Solutions, and Data, Analytics and Care Coordination. In addition, the (i) corporate general and administrative expenses (including marketing expenses) and (ii) revenue and the associated cost from the resale of certain ancillary products, primarily hardware The new reportable segments are (i) Core Clinical and Financial Solutions and (ii) Data , Analytics and Care Coordination. The new Core Clinical and Financial Solutions segment derives its revenue from the sale of software applications for patient engagement, integrated clinical and financial management solutions, which primarily include E H R -related software, financial and practice management software, related installation, support and maintenance, outsourcing, private cloud hosting and revenue cycle management. The new Data , Analytics and Care Coordination segment derives its revenue from the sale of care coordination, practice reimbursement and payer and life sciences solutions, which are mainly targeted at hospitals, health systems, other care facilities , payers, life sciences companies and other key healthcare stakeholders. These solutions enable clients to transition, analyze, coordinate care and improve the quality, efficiency and value of healthcare delivery across the entire care community. The EPSi TM operating segment is included in the “Unallocated Amounts” category as it does not meet the requirements to be a reportable segment nor the criteria to be aggregated into the two reportable segments. The segment disclosures below for the three and nine months ended September 3 0 , 2019 have been revised to conform to the current year presentation. Our Chief Operating Decision Maker (“CODM”) uses segment revenues, gross profit and income (loss) from operations as measures of performance and to make decisions about the allocation of resources. We do not track our assets by segment. Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2020 2019 2020 2019 Revenue: Core Clinical and Financial Solutions $ 306,451 $ 343,016 $ 937,882 $ 1,031,210 Data, Analytics and Care Coordination 88,834 91,295 262,353 261,686 Unallocated Amounts 6,745 9,873 24,731 27,797 Total revenue $ 402,030 $ 444,184 $ 1,224,966 $ 1,320,693 Gross profit: Core Clinical and Financial Solutions $ 104,045 $ 115,403 $ 312,901 $ 357,850 Data, Analytics and Care Coordination 52,402 53,382 153,099 156,788 Unallocated Amounts 5,150 6,517 17,042 18,881 Total gross profit $ 161,597 $ 175,302 $ 483,042 $ 533,519 Income (loss) from operations: Core Clinical and Financial Solutions $ (8,387 ) $ (9,514 ) $ (45,132 ) $ (26,772 ) Data, Analytics and Care Coordination 15,039 9,548 31,971 26,402 Unallocated Amounts 2,727 3,148 8,594 10,940 Total income (loss) from operations $ 9,379 $ 3,182 $ (4,567 ) $ 10,570

Supplemental Disclosures

Supplemental Disclosures	9 Months Ended
	Sep. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Disclosures	16. Supplemental Disclosures Supplemental Consolidated Statements of Cash Flows Information The majority of the restricted cash balance as of September 30, 2020 and 2019 represents the remaining balance of the escrow account established as part of the acquisition of Netsmart in 2016, to be used by Netsmart to facilitate the integration of Allscripts’ former Homecare TM September 30, (In thousands) 2020 2019 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 218,701 $ 129,349 Restricted cash 6,209 9,375 Total cash, cash equivalents and restricted cash $ 224,910 $ 138,724 Nine Months Ended September 30, (In thousands) 2020 2019 Supplemental non-cash information: Issuance of treasury stock to commercial partner $ 752 $ 701

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events On October 12, 2020, we signed a purchase agreement (the “CarePort Purchase Agreement”) with a subsidiary of WellSky Corp., a Delaware corporation (“WellSky”), pursuant to which WellSky has agreed to purchase substantially all of the assets of our CarePort Health business, and to assume certain liabilities in connection therewith, for $1.35 billion, subject to certain adjustments and upon the terms and conditions set forth in the CarePort Purchase Agreement. The transactions contemplated by the CarePort Purchase Agreement are subject to customary closing conditions, including the applicable waiting period (and any extensions thereof) under the Hart-Scott-Rodino Antitrust Improvements Act having expired or otherwise having been terminated. On October 15, 2020, we completed the transactions contemplated by the EPSi Purchase Agreement, by which Strata purchased substantially all of the assets of the EPSi TM TM

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three and nine months ended September 30, 2020 and 2019 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting. The Company believes that the disclosures made are adequate to make these unaudited interim consolidated financial statements not misleading. They should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2019 (our “Form 10-K”).
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Our estimates and assumptions consider the economic implications of COVID-19 on our critical and significant accounting estimates. Actual results could differ materially from these estimates.
Change in Presentation	Change in Presentation During the first quarter of 2020, we changed our reportable segments from Provider, Veradigm and Unallocated to Core Clinical and Financial Solutions, Data, Analytics and Care Coordination, and Unallocated. The business units reported within the historical segments have been reallocated into the new segments. Refer to Note 15 “Business Segments” for further discussion on the impact of the change. Certain reclassifications were made to prior period amounts in order to conform to the current period presentation. These reclassifications had no impact on the reported consolidated prior period financial results.
Recently Adopted Accounting Pronouncements	Significant Accounting Policies We adopted Accounting Standards Update No. 2016-13, “ Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Recently Adopted Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2018-13, “Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” In March 2020, the FASB issued Accounting Standards Update No. 2020-04, “Reference Rate Reform (Topic 848) – Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”), which provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in ASU 2020-04 apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 will be effective for all entities as of March 12, 2020 through December 31, 2022. We adopted ASU 2020-04 on March 12, 2020, and the adoption had no impact on our consolidated financial statements.
Accounting Pronouncements Not Yet Adopted	Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued Accounting Standards Update No. 2019-12, “ Income Taxes (Topic 740) In August 2020, the FASB issued Accounting Standards Update No. 2020-06, “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, will have a material impact on our consolidated financial statements.
Revenue Recognition	Revenue Recognition We recognize revenue only when we satisfy an identified performance obligation (or bundle of obligations) by transferring control of a promised product or service to a customer. We consider a product or service to be transferred when a customer obtains control because a customer has sole possession of the right to use (or the right to direct the use of) the product or service for the remainder of its economic life or to consume the product or service in its own operations. We evaluate the transfer of control primarily from the customer’s perspective as this reduces the risk that revenue is recognized for activities that do not transfer control to the customer. The majority of our revenue is recognized over time because a customer continuously and simultaneously receives and consumes the benefits of our performance. The exceptions to this pattern are our sales of perpetual and term software licenses, and hardware, where we determined that a customer obtains control of the asset upon granting of access, delivery or shipment.

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	9 Months Ended
	Sep. 30, 2020
Summary of Revenue Recognized on Various Performance Obligations and Elected Accounting Expedients	The breakdown of revenue recognized based on the origination of performance obligations and elected accounting expedients is presented in the table below: (In thousands) Three Months Ended March 31, 2020 Three Months Ended June 30, 2020 Three Months Ended September 30, 2020 Revenue related to deferred revenue balance at beginning of period $ 140,132 $ 155,616 $ 154,000 Revenue related to new performance obligations satisfied during the period 216,990 196,110 193,370 Revenue recognized under "right-to-invoice" expedient 58,059 54,082 54,313 Reimbursed travel expenses, shipping and other revenue 1,532 415 347 Total revenue $ 416,713 $ 406,223 $ 402,030 (In thousands) Three Months Ended March 31, 2019 Three Months Ended June 30, 2019 Three Months Ended September 30, 2019 Revenue related to deferred revenue balance at beginning of period $ 126,184 $ 146,150 $ 151,543 Revenue related to new performance obligations satisfied during the period 248,221 233,696 228,927 Revenue recognized under "right-to-invoice" expedient 55,923 62,245 61,814 Reimbursed travel expenses, shipping and other revenue 1,721 2,369 1,900 Total revenue $ 432,049 $ 444,460 $ 444,184
Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments	The below tables summarize revenue by type and nature of revenue stream as well as by our reportable segments: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2020 2019 2020 2019 Revenue: Recurring revenue $ 333,900 $ 349,455 $ 1,010,207 $ 1,048,204 Non-recurring revenue 68,130 94,729 214,759 272,489 Total revenue $ 402,030 $ 444,184 $ 1,224,966 $ 1,320,693
Summary of Changes in Estimate of Credit Losses for Contract Assets	Changes in the estimate of credit losses for contract assets are presented in the table below. (In thousands) Total Balance at January 1, 2020 $ 5,341 Current period provision 0 Balance at September 30, 2020 $ 5,341 Less: Contract assets, short-term 1,068 Total contract assets, long-term $ 4,273
Revenue by Segment [Member]
Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments	Three Months Ended September 30, 2020 (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts Total Software delivery, support and maintenance $ 160,858 $ 85,231 $ 4,458 $ 250,547 Client services 145,593 3,603 2,287 151,483 Total revenue $ 306,451 $ 88,834 $ 6,745 $ 402,030 Three Months Ended September 30, 2019 (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts Total Software delivery, support and maintenance $ 191,280 $ 85,603 $ 7,490 $ 284,373 Client services 151,736 5,692 2,383 159,811 Total revenue $ 343,016 $ 91,295 $ 9,873 $ 444,184 Nine Months Ended September 30, 2020 (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts Total Software delivery, support and maintenance $ 502,159 $ 251,027 $ 16,994 $ 770,180 Client services 435,723 11,326 7,737 454,786 Total revenue $ 937,882 $ 262,353 $ 24,731 $ 1,224,966 Nine Months Ended September 30, 2019 (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts Total Software delivery, support and maintenance $ 574,715 $ 250,059 $ 20,134 $ 844,908 Client services 456,495 11,627 7,663 475,785 Total revenue $ 1,031,210 $ 261,686 $ 27,797 $ 1,320,693

Accounts Receivables (Tables)

Accounts Receivables (Tables)	9 Months Ended
	Sep. 30, 2020
Trade Accounts Receivable [Member]
Accounts Notes And Loans Receivable [Line Items]
Schedule of Changes in Estimate of Credit Losses for Trade Accounts Receivable	Changes in the estimate of credit losses for trade accounts receivable are presented in the tables below. (In thousands) Total Balance at January 1, 2020 $ 36,490 Current period provision 9,164 Write-offs (8,286 ) Recoveries 73 Less: Reclassified allowance against receivables held for sale (1) (416 ) Balance at September 30, 2020 $ 37,025 (1 ) During the three months ended September 30, 2020, a portion of accounts receivable and the allowance thereon were reclassified to current assets held for sale in the accompanying consolidated balance sheets due to the Company’s entry into an asset purchase agreement with Strata Decision Technology LLC, to sell the EPSi TM TM

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2020
Lessee Disclosure [Abstract]
Summary of Operating Costs Associated with Leased Assets	Operating costs associated with leased assets are as follows: (In thousands) Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Operating lease cost (1) $ 6,430 $ 7,113 $ 19,791 $ 20,881 Less: Sublease income (257 ) (824 ) (1,026 ) (2,404 ) Total operating lease costs $ 6,173 $ 6,289 $ 18,765 $ 18,477 (1) Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statements of operations.
Supplemental Information for Operating Leases	Supplemental information for operating leases is as follows: (In thousands) Nine Months Ended September 30, 2020 2019 Operating cash flows from operating leases $ 21,082 $ 22,211 Right-of-use assets obtained in exchange for operating lease obligations $ 23,355 $ 144,080
Summary of Balance Sheet Location and Balances for Operating Leases	The balance sheet location and balances for operating leases are as follows: (In thousands, except lease term and discount rate) September 30, 2020 December 31, 2019 Right-of-use assets - operating leases $ 102,217 $ 98,020 Current operating lease liabilities $ 22,317 $ 23,137 Long-term operating lease liabilities $ 98,866 $ 95,162 Weighted average remaining lease term (in years) 6 6 Weighted average discount rate 3.6 % 4.4 %
Summary of Future Maturities of Lease and Non-Lease Components	The future maturities of our leasing arrangements including lease and non-lease components are shown in the below table. The maturities are calculated using foreign currency exchange rates in effect as of September 30, 2020. September 30, 2020 (In thousands) Operating Leases Remainder of 2020 $ 6,593 2021 26,763 2022 25,068 2023 22,856 2024 17,267 Thereafter 36,667 Total lease liabilities 135,214 Less: Amount representing interest (13,059 ) Less: Reclassified lease liabilities held for sale (1) (972 ) Less: Short-term lease liabilities (22,317 ) Total long-term lease liabilities $ 98,866 (1) TM TM

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2020
Business Combinations [Abstract]
Summary of Components of Assets and Liabilities Classified as Held-for-Sale	The following table provides the components of those assets and liabilities related to the EPSi Purchase Agreement which are classified as held-for-sale as of September 30, 2020: (In thousands) September 30, 2020 Assets held for sale: Current assets: Accounts receivable, net of allowance of $416 $ 10,088 Contract assets 4,147 Prepaid expenses and other current assets 956 Total current assets classified as held for sale 15,191 Fixed assets, net 254 Software development costs, net 10,977 Goodwill 74,663 Contract assets - long-term 2,765 Right-of-use assets - operating leases 932 Total assets held for sale $ 104,782 Liabilities related to assets held for sale: Current liabilities: Accrued expenses $ 964 Accrued compensation and benefits 1,714 Deferred revenue 13,400 Current operating lease liabilities 371 Total current liabilities classified as held for sale 16,449 Deferred revenue 429 Long-term operating lease liabilities 601 Total liabilities related to assets held for sale $ 17,479

Fair Value Measurements and L_2

Fair Value Measurements and Long-term Investments (Tables)	9 Months Ended
	Sep. 30, 2020
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet September 30, 2020 December 31, 2019 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Foreign exchange derivative assets Prepaid expenses and other current assets $ 0 $ 1,620 $ 0 $ 1,620 $ 0 $ 0 $ 0 $ 0 1.25% Call Option Other assets 0 0 0 0 0 0 84 84 Total assets $ 0 $ 1,620 $ 0 $ 1,620 $ 0 $ 0 $ 84 $ 84 Contingent consideration - current Accrued expenses $ 0 $ 0 $ 16,115 $ 16,115 $ 0 $ 0 $ 17,116 $ 17,116 Contingent consideration - long-term Other liabilities 0 0 0 0 0 0 2,415 2,415 1.25% Embedded cash conversion option Other liabilities 0 0 0 0 0 0 185 185 Total liabilities $ 0 $ 0 $ 16,115 $ 16,115 $ 0 $ 0 $ 19,716 $ 19,716
Summary of Changes in Assets and Liabilities Measured at Fair Value on Recurring Basis	The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at September 30, 2020 are summarized as follows: (In thousands) Contingent Consideration 1.25% Notes Call Spread Overlay Balance at December 31, 2019 $ 19,531 $ (101 ) Additions 773 0 Payments (4,189 ) 0 Fair value adjustments 0 101 Balance at September 30, 2020 $ 16,115 $ 0
Summary of Quantitative Information About Fair Value Measurements	The following table summarizes the quantitative information about our Level 3 fair value measurements at September 30, 2020: September 30, 2020 (In thousands, except the discount rate) Fair Value Valuation Technique Significant Unobservable Inputs Ranges of Inputs Weighted Average (1) Financial instruments: Contingent consideration $ 16,115 Probability Weighted Discounted cash flow Discount rate 4% to 5% 4 % Revenue $0 to $62,500 $ 31,250 Registry members 0 to 1,551 776 Patient data volume 0 to 52,845 26,422 Projected year of payment 2020 to 2021 Total financial instruments $ 16,115 (1) The weighted average is calculated based upon the absolute fair value of the instruments.
Long-Term Equity and Cost Method Investments [Member]
Summary of Long-term Equity Investments Included in Other Assets	The following table summarizes our long-term equity investments which are included in Other assets in the accompanying consolidated balance sheets: Number of Investees Original Carrying Value at (In thousands, except for number of investees) at September 30, 2020 Cost September 30, 2020 December 31, 2019 Equity method investments (1) 3 $ 7,099 $ 11,051 $ 11,332 Cost less impairment 8 37,568 24,995 32,462 Total long-term equity investments 11 $ 44,667 $ 36,046 $ 43,794 (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Share-Based Compensation Expense	Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2020 2019 2020 2019 Cost of revenue: Software delivery, support and maintenance $ 295 $ 395 $ 1,213 $ 1,522 Client services 1,519 765 3,418 3,021 Total cost of revenue 1,814 1,160 4,631 4,543 Selling, general and administrative expenses 6,728 5,643 18,851 20,799 Research and development 2,127 1,677 5,950 7,125 Total stock-based compensation expense $ 10,669 $ 8,480 $ 29,432 $ 32,467
Share-Based Awards Granted	We granted stock-based awards as follows: Three Months Ended September 30, 2020 Nine Months Ended September 30, 2020 Weighted-Average Weighted-Average Grant Date Grant Date (In thousands, except per share amounts) Shares Fair Value Shares Fair Value Service-based restricted stock units 90 $ 8.90 4,508 $ 6.44 Performance-based restricted stock units with a service condition 504 $ 7.19 504 $ 7.19 Market-based restricted stock units with a service condition 0 $ 0.00 595 $ 9.98 594 $ 7.45 5,607 $ 6.88

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Calculations of Earnings (Loss) Per Share	The calculations of earnings (loss) per share are as follows: Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except per share amounts) 2020 2019 2020 2019 Basic earnings (loss) per Common Share: Net income (loss) $ 542 $ (5,725 ) $ (27,417 ) $ (163,632 ) Net loss attributable to non-controlling interests 0 0 0 424 Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders $ 542 $ (5,725 ) $ (27,417 ) $ (163,208 ) Weighted-average common shares outstanding 161,144 166,391 162,092 167,610 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share $ 0.00 $ (0.03 ) $ (0.17 ) $ (0.97 ) Diluted earnings (loss) per Common Share: Net income (loss) $ 542 $ (5,725 ) $ (27,417 ) $ (163,632 ) Net loss attributable to non-controlling interests 0 0 0 424 Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders $ 542 $ (5,725 ) $ (27,417 ) $ (163,208 ) Weighted-average common shares outstanding 161,144 166,391 162,092 167,610 Plus: Dilutive effect of stock options, restricted stock unit awards and warrants 2,168 0 0 0 Weighted-average common shares outstanding assuming dilution 163,312 166,391 162,092 167,610 Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share $ 0.00 $ (0.03 ) $ (0.17 ) $ (0.97 )
Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share	The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2020 2019 2020 2019 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 47,162 27,969 48,816 27,350

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and intangible assets consist of the following: September 30, 2020 December 31, 2019 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 546,289 $ (463,298 ) $ 82,991 $ 546,373 $ (437,640 ) $ 108,733 Customer contracts and relationships 701,976 (507,956 ) 194,020 702,034 (488,625 ) 213,409 Total $ 1,248,265 $ (971,254 ) $ 277,011 $ 1,248,407 $ (926,265 ) $ 322,142 Intangibles not subject to amortization: Registered trademarks $ 52,000 $ 52,000 Goodwill 1,287,197 1,362,017 Total $ 1,339,197 $ 1,414,017
Changes in Carrying Amount of Goodwill	Changes in the carrying amounts of goodwill by reportable segment for the nine months ended September 30, 2020 were as follows: (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts (2) Total Balance as of December 31, 2019 734,883 552,471 74,663 1,362,017 Foreign exchange translation (157 ) 0 0 (157 ) Reclassification to assets held for sale (1) 0 0 (74,663 ) (74,663 ) Balance as of September 30, 2020 $ 734,726 $ 552,471 $ 0 $ 1,287,197 (1) During the three months ended September 30, 2020, the carrying amount of goodwill assigned to the EPSi TM TM TM ( 2 ) The EPSi TM

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Instrument [Line Items]
Debt Outstanding Excluding Lease Obligations	Debt outstanding, excluding lease obligations, consists of the following: September 30, 2020 December 31, 2019 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 0.875% Convertible Senior Notes (1) $ 167,853 $ (1,712 ) $ 169,565 $ 177,942 $ 4,697 $ 173,245 1.25% Cash Convertible Senior Notes 0 0 0 345,000 7,552 337,448 Senior Secured Credit Facility 910,000 5,224 904,776 410,000 5,224 404,776 Total debt $ 1,077,853 $ 3,512 $ 1,074,341 $ 932,942 $ 17,473 $ 915,469 Less: Debt payable within one year 49,000 707 48,293 364,653 188 364,465 Total long-term debt, less current maturities $ 1,028,853 $ 2,805 $ 1,026,048 $ 568,289 $ 17,285 $ 551,004 (1) Principal balance is $207,911 thousand; $167,853 thousand is recognized in debt and $40,058 thousand is recognized in additional paid-in capital
Interest Expense	Interest expense consists of the following: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2020 2019 2020 2019 Interest expense $ 5,646 $ 6,741 $ 17,833 $ 19,404 Amortization of discounts and debt issuance costs 2,016 4,098 13,447 12,043 Total interest expense $ 7,662 $ 10,839 $ 31,280 $ 31,447
Summary of Future Debt Payment Obligations	The following table summarizes future debt payment obligations as of September 30, 2020: (In thousands) Total Remainder of 2020 2021 2022 2023 2024 Thereafter 0.875% Convertible Senior Notes (1) $ 207,911 $ 0 $ 0 $ 0 $ 0 $ 0 $ 207,911 Term Loan 310,000 26,500 30,000 37,500 216,000 0 0 Revolving Facility (2) 600,000 0 0 0 600,000 0 0 Total debt $ 1,117,911 $ 26,500 $ 30,000 $ 37,500 $ 816,000 $ 0 $ 207,911 (1) Amount represents face value of the 0.875% Convertible Senior Notes, which includes both the liability and equity portion. ( 2 ) Assumes no additional borrowings after September 30, 2020, payment of any required periodic installments of principal and that all drawn amounts are repaid upon maturity.
0.875% Convertible Senior Notes and the 1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Interest Expense Related to 0.875% Convertible Senior Notes and 1.25% Cash Convertible Senior Notes	Interest expense related to the 0.875% Convertible Senior Notes and the 1.25% Cash Convertible Senior Notes, included in the table above, consisted of the following: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2020 2019 2020 2019 Coupon interest $ 451 $ 1,078 $ 3,561 $ 3,234 Amortization of discounts and debt issuance costs 1,454 3,685 12,030 10,876 Total interest expense related to the convertible notes $ 1,905 $ 4,763 $ 15,591 $ 14,110

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Effective Tax Rates	The effective tax rates were as follows: Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except effective tax rate) 2020 2019 2020 2019 Income (loss) before income taxes $ 1,473 $ (6,490 ) $ (19,960 ) $ (162,992 ) Income tax (provision) benefit $ (931 ) $ 765 $ (7,457 ) $ (640 ) Effective tax rate 63.2 % 11.8 % (37.4 %) (0.4 %)

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2020
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Fair Value and Balance Sheet Locations	The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: September 30, 2020 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 1,620 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 0 N/A 1.25% Embedded cash conversion option N/A Other liabilities 0 Total derivatives $ 1,620 $ 0 December 31, 2019 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 0 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 84 N/A 1.25% Embedded cash conversion option N/A Other liabilities 185 Total derivatives $ 84 $ 185 N/A – We define “N/A” as disclosure not being applicable
Derivatives Instruments Designated as Cash Flow Hedges	The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss: Amount of Gain (Loss) Recognized in OCI Amount of Gain (Loss) Reclassified from AOCI into Income (In thousands) Three Months Ended September 30, 2020 Nine Months Ended September 30, 2020 Location of Gain (Loss) Reclassified from AOCI into Income Three Months Ended September 30, 2020 Nine Months Ended September 30, 2020 Foreign exchange contracts $ 1,280 $ 1,798 Cost of Revenue $ 107 $ 71 Selling, general and administrative expenses 52 34 Research and development $ 111 $ 73 Amount of Gain (Loss) Recognized in OCI Amount of Gain (Loss) Reclassified from AOCI into Income (In thousands) Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 Location of Gain (Loss) Reclassified from AOCI into Income Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 Foreign exchange contracts $ (257 ) $ 83 Cost of Revenue $ 16 $ 76 Selling, general and administrative expenses 12 53 Research and development $ 19 $ 85
Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option	The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes’ embedded cash conversion option in the consolidated statements of operations: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2020 2019 2020 2019 1.25% Call Option $ 0 $ (3,567 ) $ (84 ) $ (6,262 ) 1.25% Embedded cash conversion option 0 3,746 185 6,355 Net income included in Other income, net $ 0 $ 179 $ 101 $ 93

Other Comprehensive Income (Tab

Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Components of Accumulated Other Comprehensive Loss	Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2019 (1) $ (4,392 ) $ 0 $ (4,392 ) Other comprehensive loss (income) before reclassifications (611 ) 1,334 723 Net losses (gains) reclassified from accumulated other comprehensive loss 0 (132 ) (132 ) Net other comprehensive (loss) income (611 ) 1,202 591 Balance as of September 30, 2020 (2) $ (5,003 ) $ 1,202 $ (3,801 ) (1) (2) (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2018 (1) $ (5,584 ) $ 195 $ (5,389 ) Other comprehensive income (loss) before reclassifications (35 ) 61 26 Net (gains) losses reclassified from accumulated other comprehensive loss 0 (158 ) (158 ) Net other comprehensive income (35 ) (97 ) (132 ) Balance as of September 30, 2019 (2) $ (5,619 ) $ 98 $ (5,521 ) (1) (2)
Income Tax Effects Related to Components of Other Comprehensive Income (Loss)	The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended September 30, 2020 2019 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 983 $ 0 $ 983 $ (574 ) $ 0 $ (574 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 1,280 (330 ) 950 (257 ) 67 (190 ) Net losses (gains) reclassified into income (271 ) 70 (201 ) (48 ) 13 (35 ) Net change in unrealized gains (losses) on foreign exchange contracts 1,009 (260 ) 749 (305 ) 80 (225 ) Net gain (loss) on cash flow hedges 1,009 (260 ) 749 (305 ) 80 (225 ) Other comprehensive income (loss) $ 1,992 $ (260 ) $ 1,732 $ (879 ) $ 80 $ (799 ) Nine Months Ended September 30, 2020 2019 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ (611 ) $ 0 $ (611 ) $ (35 ) $ 0 $ (35 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 1,798 (464 ) 1,334 83 (22 ) 61 Net losses (gains) reclassified into income (178 ) 46 (132 ) (214 ) 56 (158 ) Net change in unrealized gains (losses) on foreign exchange contracts 1,620 (418 ) 1,202 (131 ) 34 (97 ) Net gain (loss) on cash flow hedges 1,620 (418 ) 1,202 (131 ) 34 (97 ) Other comprehensive (loss) income $ 1,009 $ (418 ) $ 591 $ (166 ) $ 34 $ (132 )

Business Segments (Tables)

Business Segments (Tables)	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Revenues and Income (Loss) from Operations Related to Segment Within Reconciliation to Consolidated Amounts	Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2020 2019 2020 2019 Revenue: Core Clinical and Financial Solutions $ 306,451 $ 343,016 $ 937,882 $ 1,031,210 Data, Analytics and Care Coordination 88,834 91,295 262,353 261,686 Unallocated Amounts 6,745 9,873 24,731 27,797 Total revenue $ 402,030 $ 444,184 $ 1,224,966 $ 1,320,693 Gross profit: Core Clinical and Financial Solutions $ 104,045 $ 115,403 $ 312,901 $ 357,850 Data, Analytics and Care Coordination 52,402 53,382 153,099 156,788 Unallocated Amounts 5,150 6,517 17,042 18,881 Total gross profit $ 161,597 $ 175,302 $ 483,042 $ 533,519 Income (loss) from operations: Core Clinical and Financial Solutions $ (8,387 ) $ (9,514 ) $ (45,132 ) $ (26,772 ) Data, Analytics and Care Coordination 15,039 9,548 31,971 26,402 Unallocated Amounts 2,727 3,148 8,594 10,940 Total income (loss) from operations $ 9,379 $ 3,182 $ (4,567 ) $ 10,570

Supplemental Disclosures (Table

Supplemental Disclosures (Tables)	9 Months Ended
	Sep. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Disclosures	The majority of the restricted cash balance as of September 30, 2020 and 2019 represents the remaining balance of the escrow account established as part of the acquisition of Netsmart in 2016, to be used by Netsmart to facilitate the integration of Allscripts’ former Homecare TM September 30, (In thousands) 2020 2019 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 218,701 $ 129,349 Restricted cash 6,209 9,375 Total cash, cash equivalents and restricted cash $ 224,910 $ 138,724 Nine Months Ended September 30, (In thousands) 2020 2019 Supplemental non-cash information: Issuance of treasury stock to commercial partner $ 752 $ 701

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)	Sep. 30, 2020
Accounting Standards Update 2016-13 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 1, 2020
Accounting Standards Update 2018-13 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 1, 2020
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	true
Accounting Standards Update 2020-04 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Mar. 12, 2020
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	true

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Additional Information (Detail) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)Revenue_Stream	Sep. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jan. 01, 2020USD ($)	Dec. 31, 2019USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2018USD ($)
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Number of primary revenue streams | Revenue_Stream			2
Total backlog	$ 4,400,000		$ 4,400,000
Total backlog, percentage, year one	27.00%		27.00%
Total backlog, percentage after year one	73.00%		73.00%
Cumulative impact on retained earnings (accumulated deficit)	$ 1,208,387	$ 1,281,058	$ 1,208,387	$ 1,281,058	$ 1,242,929		$ 1,285,188	$ 1,316,207	$ 1,580,427
ASU 2016-13 | Cumulative Effect, Period of Adoption, Adjustment
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Cumulative impact on retained earnings (accumulated deficit)						$ (5,300)
Selling, General and Administrative Expenses [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost Amortization	6,800	$ 7,500	20,900	$ 22,500
Prepaid Expenses and Other Current Assets [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost, Gross	18,800		18,800				20,800
Other Assets [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost, Gross	$ 32,800		$ 32,800				$ 32,900

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Summary of Revenue Recognized on Various Performance Obligations and Elected Accounting Expedients (Detail) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue From Contract With Customer [Abstract]
Revenue related to deferred revenue balance at beginning of period	$ 154,000	$ 155,616	$ 140,132	$ 151,543	$ 146,150	$ 126,184
Revenue related to new performance obligations satisfied during the period	193,370	196,110	216,990	228,927	233,696	248,221
Revenue recognized under "right-to-invoice" expedient	54,313	54,082	58,059	61,814	62,245	55,923
Reimbursed travel expenses, shipping and other revenue	347	415	1,532	1,900	2,369	1,721
Total revenue	$ 402,030	$ 406,223	$ 416,713	$ 444,184	$ 444,460	$ 432,049	$ 1,224,966	$ 1,320,693

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation Of Revenue [Line Items]
Recurring revenue	$ 333,900			$ 349,455			$ 1,010,207	$ 1,048,204
Non-recurring revenue	68,130			94,729			214,759	272,489
Total revenue	402,030	$ 406,223	$ 416,713	444,184	$ 444,460	$ 432,049	1,224,966	1,320,693
Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	6,745			9,873			24,731	27,797
Core Clinical and Financial Solutions [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	306,451			343,016			937,882	1,031,210
Data Analytics and Care Coordination [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	88,834			91,295			262,353	261,686
Software delivery, Support and Maintenance [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	250,547			284,373			770,180	844,908
Software delivery, Support and Maintenance [Member] | Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	4,458			7,490			16,994	20,134
Software delivery, Support and Maintenance [Member] | Core Clinical and Financial Solutions [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	160,858			191,280			502,159	574,715
Software delivery, Support and Maintenance [Member] | Data Analytics and Care Coordination [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	85,231			85,603			251,027	250,059
Client services [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	151,483			159,811			454,786	475,785
Client services [Member] | Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	2,287			2,383			7,737	7,663
Client services [Member] | Core Clinical and Financial Solutions [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	145,593			151,736			435,723	456,495
Client services [Member] | Data Analytics and Care Coordination [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 3,603			$ 5,692			$ 11,326	$ 11,627

Revenue from Contracts with C_6

Revenue from Contracts with Customers - Summary of Changes in Estimate of Credit Losses for Contract Assets (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Revenue From Contract With Customer [Abstract]
Balance at January 1, 2020	$ 5,341
Current period provision	0
Balance at September 30, 2020	5,341
Contract assets, allowance	1,068	$ 0
Total contract assets, long-term	$ 4,273	$ 0

Accounts Receivables - Addition

Accounts Receivables - Additional Information (Details) - Trade Accounts Receivable [Member] - USD ($) $ in Thousands	Sep. 30, 2020	Jan. 01, 2020	Dec. 31, 2019
Accounts Notes And Loans Receivable [Line Items]
Accounts receivable, allowance for credit loss	$ 37,025		$ 36,490
ASU 2016-13
Accounts Notes And Loans Receivable [Line Items]
Accounts receivable, allowance for credit loss		$ 12,600

Accounts Receivables - Schedule

Accounts Receivables - Schedule of Changes in Estimate of Credit Losses for Trade Accounts Receivable (Details) - Trade Accounts Receivable [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Accounts Notes And Loans Receivable [Line Items]
Balance at January 1, 2020	$ 36,490
Current period provision	9,164
Write-offs	(8,286)
Recoveries	73
Less: Reclassified allowance against receivables held for sale	(416)
Balance at September 30, 2020	$ 37,025

Leases - Additional Information

Leases - Additional Information (Detail) - Maximum [Member]	9 Months Ended
	Sep. 30, 2020
Lessee Lease Description [Line Items]
Operating leases, remaining lease terms	8 years
Operating leases, options to extend leases term	5 years
Operating leases, options to terminate leases term	1 year

Leases - Summary of Operating C

Leases - Summary of Operating Costs Associated with Leased Assets (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Operating lease cost	[1]	$ 6,430	$ 7,113	$ 19,791	$ 20,881
Less: Sublease income		(257)	(824)	(1,026)	(2,404)
Total operating lease costs		$ 6,173	$ 6,289	$ 18,765	$ 18,477
[1]	Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statements of operations.

Leases - Supplemental Informati

Leases - Supplemental Information for Operating Leases (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Operating cash flows from operating leases	$ 21,082	$ 22,211
Right-of-use assets obtained in exchange for operating lease obligations	$ 23,355	$ 144,080

Leases - Summary of Balance She

Leases - Summary of Balance Sheet Location and Balances for Operating Leases (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Leases [Abstract]
Right-of-use assets - operating leases	$ 102,217	$ 98,020
Current operating lease liabilities	22,317	23,137
Long-term operating lease liabilities	$ 98,866	$ 95,162
Weighted average remaining lease term (in years)	6 years	6 years
Weighted average discount rate	3.60%	4.40%

Leases - Summary of Future Matu

Leases - Summary of Future Maturities of Lease and Non-Lease Components (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Operating Leases [Abstract]
Operating Leases, Remainder of 2020	$ 6,593
Operating Leases, 2021	26,763
Operating Leases, 2022	25,068
Operating Leases, 2023	22,856
Operating Leases, 2024	17,267
Operating Leases, Thereafter	36,667
Operating Leases, Total lease liabilities	135,214
Operating Leases, Less: Amount representing interest	(13,059)
Reclassified lease liabilities held for sale	(972)
Operating Leases, Less: Short-term lease liabilities	(22,317)	$ (23,137)
Operating Leases, Total long-term lease liabilities	$ 98,866	$ 95,162

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($)	Jul. 30, 2020	Jul. 02, 2019	Mar. 01, 2019
EPSi Purchase Agreement [Member] | Strata Decision Technology LLC [Member]
Business Acquisition [Line Items]
Sale of business unit	$ 365,000,000
ACC Pinnacle and Diabetes Collaborative Registries [Member]
Business Acquisition [Line Items]
Total purchase price		$ 19,700,000
Purchase price initial payment		11,700,000
Potential milestone/earnout payments		5,000,000
ACC Pinnacle and Diabetes Collaborative Registries [Member] | Maximum [Member]
Business Acquisition [Line Items]
Potential milestone/earnout payments		$ 8,000,000
Pulse8, Inc. [Member]
Business Acquisition [Line Items]
Acquisition of outstanding minority interest			$ 53,800,000

Business Combinations - Summary

Business Combinations - Summary of Components of Assets and Liabilities Classified as Held-for-Sale (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Total assets held for sale	$ 104,782	$ 0
Current liabilities:
Total liabilities related to assets held for sale	17,479	$ 0
EPSi Purchase Agreement [Member]
Current assets:
Accounts receivable, net of allowance of $416	10,088
Contract assets	4,147
Prepaid expenses and other current assets	956
Total current assets classified as held for sale	15,191
Fixed assets, net	254
Software development costs, net	10,977
Goodwill	74,663
Contract assets - long-term	2,765
Right-of-use assets - operating leases	932
Total assets held for sale	104,782
Current liabilities:
Accrued expenses	964
Accrued compensation and benefits	1,714
Deferred revenue	13,400
Current operating lease liabilities	371
Total current liabilities classified as held for sale	16,449
Deferred revenue	429
Long-term operating lease liabilities	601
Total liabilities related to assets held for sale	$ 17,479

Business Combinations - Summa_2

Business Combinations - Summary of Components of Assets and Liabilities Classified as Held-for-Sale (Parenthetical) (Detail) $ in Thousands	Sep. 30, 2020USD ($)
EPSi Purchase Agreement [Member]
Business Acquisition [Line Items]
Accounts receivable net of allowance	$ 416

Fair Value Measurements and L_3

Fair Value Measurements and Long-term Investments - Additional Information (Detail) - USD ($) $ in Thousands	Jul. 01, 2020	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Maturity date					Jul. 1, 2020
Gain from sale of a third-party equity method investment					$ 16,800
Impairment (recovery) of long-term investments		$ 1,025	$ 600	$ 0	$ 1,575	$ (1,045)
1.25% Cash Convertible Senior Notes [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate	1.25%						1.25%
Maturity date	Jul. 1, 2020				Jul. 1, 2020
1.25% Call Option [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate		1.25%			1.25%
1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate		1.25%			1.25%

Fair Value Measurements and L_4

Fair Value Measurements and Long-term Investments - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	$ 135,869	$ 147,990
Total assets	1,620	84
Total liabilities	16,115	19,716
Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	1,620	0
Contingent Consideration Current [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	16,115	17,116
Contingent Consideration Long Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	2,415
1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	185
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	0
Total liabilities	0	0
Level 1 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Level 1 [Member] | Contingent Consideration Current [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Level 1 [Member] | Contingent Consideration Long Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 1 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	1,620	0
Total liabilities	0	0
Level 2 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	1,620	0
Level 2 [Member] | Contingent Consideration Current [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Level 2 [Member] | Contingent Consideration Long Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 2 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	84
Total liabilities	16,115	19,716
Level 3 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Level 3 [Member] | Contingent Consideration Current [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	16,115	17,116
Level 3 [Member] | Contingent Consideration Long Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	2,415
Level 3 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	185
1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	84
1.25% Call Option [Member] | Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
1.25% Call Option [Member] | Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
1.25% Call Option [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	$ 0	$ 84

Fair Value Measurements and L_5

Fair Value Measurements and Long-term Investments - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Parenthetical) (Detail)	Sep. 30, 2020
1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Interest rate	1.25%
1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Interest rate	1.25%

Fair Value Measurements and L_6

Fair Value Measurements and Long-term Investments - Summary of Changes in Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Contingent Consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at December 31, 2019	$ 19,531
Additions	773
Payments	(4,189)
Fair value adjustments	0
Balance at September 30, 2020	16,115
1.25% Notes Call Spread Overlay [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Balance at December 31, 2019	(101)
Additions	0
Payments	0
Fair value adjustments	101
Balance at September 30, 2020	$ 0

Fair Value Measurements and L_7

Fair Value Measurements and Long-term Investments - Summary of Quantitative Information About Fair Value Measurements (Detail) - Level 3 [Member]	9 Months Ended
	Sep. 30, 2020USD ($)RegistryMemberPatientDataVolume
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial instruments	$ 16,115,000
Minimum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Projected year of payment	2020
Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Projected year of payment	2021
Revenue [Member] | Minimum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs	0
Revenue [Member] | Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs	62,500,000
Revenue [Member] | Weighted Average [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs	31,250,000	[1]
Registry Members [Member] | Minimum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs | RegistryMember	0
Registry Members [Member] | Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs | RegistryMember	1,551
Registry Members [Member] | Weighted Average [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs | RegistryMember	776	[1]
Patient Data Volume [Member] | Minimum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs | PatientDataVolume	0
Patient Data Volume [Member] | Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs | PatientDataVolume	52,845
Patient Data Volume [Member] | Weighted Average [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs | PatientDataVolume	26,422	[1]
Contingent Consideration [Member] | Probability Weighted Discounted Cash Flow [Member] | Discount Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial instruments	$ 16,115,000
Contingent Consideration [Member] | Probability Weighted Discounted Cash Flow [Member] | Discount Rate [Member] | Minimum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs	4
Contingent Consideration [Member] | Probability Weighted Discounted Cash Flow [Member] | Discount Rate [Member] | Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs	5
Contingent Consideration [Member] | Probability Weighted Discounted Cash Flow [Member] | Discount Rate [Member] | Weighted Average [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs	4	[1]
[1]	The weighted average is calculated based upon the absolute fair value of the instruments.

Fair Value Measurements and L_8

Fair Value Measurements and Long-term Investments - Summary of Long-term Equity Investments Included in Other Assets (Detail) $ in Thousands		9 Months Ended
		Sep. 30, 2020USD ($)Investment	Dec. 31, 2019USD ($)
Fair Value Disclosures [Abstract]
Equity method investments, Number of Investees | Investment	[1]	3
Cost less impairments, Number of investees | Investment		8
Total long-term equity investments, Number of Investees | Investment		11
Equity method investments, Original Cost	[1]	$ 7,099
Cost less impairment, Original Cost		37,568
Total long-term equity investments, Original Cost		44,667
Equity method investments, Carrying Value	[1]	11,051	$ 11,332
Cost less impairment, Carrying Value		24,995	32,462
Total long-term equity investments, Carrying Value		$ 36,046	$ 43,794
[1]	Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Aug. 02, 2018
Class Of Stock [Line Items]
Capitalized stock-based compensation costs	$ 0	$ 0	$ 0	$ 0
Stock options granted	0	0	0	0
Share issued, exercise of options and release of stock awards			1,900,000		1,700,000
Shares settled for tax withholding			770,000	658,000
Common stock repurchased, amount			$ 55,282,000	$ 102,160,000
Repurchase of unsettled common stock			0	$ 9,301,000
August 2018 Stock Repurchase Program [Member]
Class Of Stock [Line Items]
Stock repurchase program, authorized amount						$ 250,000,000
Stock repurchase program, Value of shares yet to be purchased	$ 46,600,000		$ 46,600,000
Common stock repurchased, shares	5,000,000	3,500,000	6,500,000	9,600,000
Common stock repurchased, amount	$ 45,600,000	$ 37,100,000	$ 55,300,000	$ 102,200,000
Repurchase of unsettled common stock, shares		900,000
Repurchase of unsettled common stock		$ 9,300,000
Transaction settlement date				2019-10

Stockholders' Equity - Stock-Ba

Stockholders' Equity - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 10,669	$ 8,480	$ 29,432	$ 32,467
Cost of revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	1,814	1,160	4,631	4,543
Cost of revenue [Member] | Software delivery, Support and Maintenance [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	295	395	1,213	1,522
Cost of revenue [Member] | Client services [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	1,519	765	3,418	3,021
Selling, General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	6,728	5,643	18,851	20,799
Research and development [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 2,127	$ 1,677	$ 5,950	$ 7,125

Stockholders' Equity - Stock-_2

Stockholders' Equity - Stock-Based Awards Granted (Detail) - $ / shares shares in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	594	5,607
Weighted-Average Grant Date Fair Value, granted	$ 7.45	$ 6.88
Service-Based Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	90	4,508
Weighted-Average Grant Date Fair Value, granted	$ 8.90	$ 6.44
Performance-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	504	504
Weighted-Average Grant Date Fair Value, granted	$ 7.19	$ 7.19
Market-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	0	595
Weighted-Average Grant Date Fair Value, granted	$ 0	$ 9.98

Earnings (Loss) Per Share - Cal

Earnings (Loss) Per Share - Calculations of Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Basic earnings (loss) per Common Share:
Net income (loss)	$ 542	$ (5,725)	$ (27,417)	$ (163,632)
Net loss attributable to non-controlling interests	0	0	0	424
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ 542	$ (5,725)	$ (27,417)	$ (163,208)
Weighted-average common shares outstanding	161,144	166,391	162,092	167,610
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share	$ 0	$ (0.03)	$ (0.17)	$ (0.97)
Diluted earnings (loss) per Common Share:
Net income (loss)	$ 542	$ (5,725)	$ (27,417)	$ (163,632)
Net loss attributable to non-controlling interests	0	0	0	424
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ 542	$ (5,725)	$ (27,417)	$ (163,208)
Weighted-average common shares outstanding	161,144	166,391	162,092	167,610
Plus: Dilutive effect of stock options, restricted stock unit awards and warrants	2,168	0	0	0
Weighted-average common shares outstanding assuming dilution	163,312	166,391	162,092	167,610
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per share - Diluted	$ 0	$ (0.03)	$ (0.17)	$ (0.97)

Earnings (Loss) Per Share - Ant

Earnings (Loss) Per Share - Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share (Detail) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation	47,162	27,969	48,816	27,350

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill and Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,248,265	$ 1,248,407
Accumulated Amortization	(971,254)	(926,265)
Intangible Assets, Net	277,011	322,142
Registered trademarks	52,000	52,000
Goodwill	1,287,197	1,362,017
Total	1,339,197	1,414,017
Proprietary Technology [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	546,289	546,373
Accumulated Amortization	(463,298)	(437,640)
Intangible Assets, Net	82,991	108,733
Customer Contracts and Relationships [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	701,976	702,034
Accumulated Amortization	(507,956)	(488,625)
Intangible Assets, Net	$ 194,020	$ 213,409

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Goodwill [Line Items]
Balance as of December 31, 2019	$ 1,362,017
Foreign exchange translation	(157)
Reclassification to assets held for sale	(74,663)
Balance as of September 30, 2020	1,287,197
Unallocated Amounts [Member]
Goodwill [Line Items]
Balance as of December 31, 2019	74,663
Foreign exchange translation	0
Reclassification to assets held for sale	(74,663)
Balance as of September 30, 2020	0
Core Clinical and Financial Solutions [Member] | Operating Segments [Member]
Goodwill [Line Items]
Balance as of December 31, 2019	734,883
Foreign exchange translation	(157)
Reclassification to assets held for sale	0
Balance as of September 30, 2020	734,726
Data Analytics and Care Coordination [Member] | Operating Segments [Member]
Goodwill [Line Items]
Balance as of December 31, 2019	552,471
Foreign exchange translation	0
Reclassification to assets held for sale	0
Balance as of September 30, 2020	$ 552,471

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
Accumulated impairment losses associated with goodwill	$ 39.2	$ 39.2

Debt - Debt Outstanding Excludi

Debt - Debt Outstanding Excluding Lease Obligations (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Principal Balance	$ 1,077,853	$ 932,942
Unamortized Discount and Debt Issuance Costs	3,512	17,473
Net Carrying Amount	1,074,341	915,469
Principal Balance, Current	49,000	364,653
Unamortized Discount and Debt Issuance Costs, Current	707	188
Net Carrying Amount, Current	48,293	364,465
Principal Balance, Noncurrent	1,028,853	568,289
Unamortized Discount and Debt Issuance Costs, Noncurrent	2,805	17,285
Net Carrying Amount, Noncurrent	1,026,048	551,004
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Principal Balance	167,853	177,942
Unamortized Discount and Debt Issuance Costs	(1,712)	4,697
Net Carrying Amount	169,565	173,245
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Principal Balance	0	345,000
Unamortized Discount and Debt Issuance Costs	0	7,552
Net Carrying Amount	0	337,448
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Principal Balance	910,000	410,000
Unamortized Discount and Debt Issuance Costs	5,224	5,224
Net Carrying Amount	$ 904,776	$ 404,776

Debt - Debt Outstanding Exclu_2

Debt - Debt Outstanding Excluding Lease Obligations (Parenthetical) (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Debt recognized	$ 1,077,853	$ 932,942
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	207,911	218,000
Debt recognized	167,853	177,942
Additional Paid-In Capital [Member] | 0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Additional paid-in capital recognized	$ 40,058	$ 40,058

Debt - Interest Expense (Detail

Debt - Interest Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Debt Instrument [Line Items]
Total interest expense	$ 7,662	$ 10,839	$ 31,280	$ 31,447
Convertible Senior Notes and Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Interest expense	5,646	6,741	17,833	19,404
Amortization of discounts and debt issuance costs	2,016	4,098	13,447	12,043
Total interest expense	$ 7,662	$ 10,839	$ 31,280	$ 31,447

Debt - Interest Expense Related

Debt - Interest Expense Related to 0.875% Convertible Senior Notes and 1.25% Cash Convertible Senior Notes (Detail) - 0.875% Convertible Senior Notes and the 1.25% Cash Convertible Senior Notes [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Debt Instrument [Line Items]
Coupon interest	$ 451	$ 1,078	$ 3,561	$ 3,234
Amortization of discounts and debt issuance costs	1,454	3,685	12,030	10,876
Total interest expense related to the convertible notes	$ 1,905	$ 4,763	$ 15,591	$ 14,110

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	Oct. 29, 2020	Jul. 20, 2020	Jul. 01, 2020	Aug. 07, 2019	Feb. 15, 2018	Jun. 30, 2020	Dec. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Debt Instrument [Line Items]
Debt instrument principal amount							$ 932,942,000	$ 1,077,853,000
Debt issuance costs								$ 758,000	$ 0
Maturity date								Jul. 1, 2020
Senior Secured Term Loan [Member] | Subsequent Event [Member] | EPSi Purchase Agreement [Member]
Debt Instrument [Line Items]
Prepayment of debt	$ 20,000,000
Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Credit facility, amount available								$ 298,900,000
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount							410,000,000	910,000,000
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount							177,942,000	167,853,000
Debt instrument principal amount							$ 218,000,000	$ 207,911,000
Interest rate						0.875%	0.875%	0.875%
Debt issuance costs							$ 700,000
Percentage of semi-annual interest rate used to compute the initial fair value of the liability component							1.95%
Debt instrument, initial fair value of liability component							$ 177,900,000
Debt instrument, net carrying value of equity component								$ 17,400,000
Payments for repurchase debt instrument						$ 7,700,000
Debt instrument aggregate principal amount repurchased						10,100,000
Gain on repurchase of debt instrument						500,000
Proceeds due to termination of capped call transaction						300,000
Reduction to capped call fees						800,000
Loss in capped call						$ 500,000
0.875% Convertible Senior Notes [Member] | Additional Paid-In Capital [Member]
Debt Instrument [Line Items]
Debt instrument, equity component amount							40,058,000	40,058,000
Payments of capped call fees							17,200,000
Debt discounts and issuance costs							1,100,000
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount							$ 345,000,000	$ 0
Interest rate			1.25%				1.25%
Maturity date			Jul. 1, 2020					Jul. 1, 2020
Repayment of cash convertible senior notes			$ 345,000,000
Letter of Credit [Member]
Debt Instrument [Line Items]
Portion of facility available for issuance					$ 50,000,000
Swing Loans [Member]
Debt Instrument [Line Items]
Portion of facility available for issuance					10,000,000
Foreign Currencies [Member]
Debt Instrument [Line Items]
Portion of facility available for issuance					100,000,000
Senior Secured Term Loan [Member]
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity					$ 400,000,000
Senior secured credit facilities term, years					5 years
Line of credit facility, frequency of payments								The Term Loan is repayable in quarterly installments, which began on June 30, 2018.
Second Amended Credit Agreement [Member] | Senior Secured Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount								$ 310,000,000
Second Amended Credit Agreement [Member] | Senior Secured Term Loan [Member] | Subsequent Event [Member] | EPSi Purchase Agreement [Member]
Debt Instrument [Line Items]
Prepayment of debt	$ 19,000,000
Second Amended Credit Agreement [Member] | Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount								$ 600,000,000
Second Amended Credit Agreement [Member] | Senior Secured Revolving Facility [Member] | United States dollars [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage								2.15%
Second Amended Credit Agreement [Member] | Senior Secured Revolving Facility [Member] | LIBOR Rate [Member]
Debt Instrument [Line Items]
Debt instrument, variable interest rate								2.00%
Second Amended Credit Agreement [Member] | Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Letters of credit outstanding								$ 1,100,000
Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity					$ 900,000,000
Senior secured credit facilities term, years					5 years
Fees and other costs, incurred		$ 1,400,000		$ 800,000

Debt - Summary of Future Debt P

Debt - Summary of Future Debt Payment Obligations (Detail) $ in Thousands	Sep. 30, 2020USD ($)
Debt Instrument [Line Items]
Total	$ 1,117,911
Remainder of 2020	26,500
2021	30,000
2022	37,500
2023	816,000
2024	0
Thereafter	207,911
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Total	207,911
Remainder of 2020	0
2021	0
2022	0
2023	0
2024	0
Thereafter	207,911
Senior Secured Term Loan [Member]
Debt Instrument [Line Items]
Total	310,000
Remainder of 2020	26,500
2021	30,000
2022	37,500
2023	216,000
2024	0
Thereafter	0
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Total	600,000
Remainder of 2020	0
2021	0
2022	0
2023	600,000
2024	0
Thereafter	$ 0

Effective Tax Rates (Detail)

Effective Tax Rates (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income (loss) before income taxes	$ 1,473	$ (6,490)	$ (19,960)	$ (162,992)
Income tax (provision) benefit	$ (931)	$ 765	$ (7,457)	$ (640)
Effective tax rate	63.20%	11.80%	(37.40%)	(0.40%)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Income (loss) before income taxes	$ 1,473	$ (6,490)	$ (19,960)	$ (162,992)
Cumulative operating income loss period considered			3 years
Unrecognized income tax benefits	$ 21,400		$ 21,400		$ 20,600
U.S. and Foreign Net Operating Loss Carryforwards [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Valuation allowance			$ 1,200

Derivative Financial Instrume_3

Derivative Financial Instruments - Fair Value and Balance Sheet Locations - (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Derivatives Fair Value [Line Items]
Derivative asset, fair value	$ 1,620	$ 84
Derivative liability, fair value	0	185
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Prepaid Expenses and Other Current Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	1,620	0
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Accrued expenses [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	0	0
Not Designated as Hedging Instrument [Member] | 1.25% Call Option [Member] | Other Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	0	84
Not Designated as Hedging Instrument [Member] | 1.25% Embedded Cash Conversion Option [Member] | Other Liabilities [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	$ 0	$ 185

Derivative Financial Instrume_4

Derivative Financial Instruments - Additional Information (Detail)	Jul. 01, 2020	Sep. 30, 2020USD ($)Derivative	Sep. 30, 2020INR (₨)Derivative	Dec. 31, 2019	Jun. 18, 2013USD ($)
Derivative [Line Items]
Maturity date		Jul. 1, 2020
1.25% Call Option [Member]
Derivative [Line Items]
Debt instrument interest rate		1.25%	1.25%
1.25% Cash Convertible Senior Notes [Member]
Derivative [Line Items]
Maturity date	Jul. 1, 2020	Jul. 1, 2020
Debt instrument interest rate	1.25%			1.25%
Foreign Exchange Forward Contracts [Member]
Derivative [Line Items]
Number of contracts | Derivative		9	9
Unrealized derivatives gains included in accumulated other comprehensive (loss) income reclassified into income		$ 1,600,000
Estimated period of unrealized losses included in AOCI reclassified into income		9 months
Foreign Exchange Forward Contracts [Member] | Minimum [Member]
Derivative [Line Items]
Date of contracts mature		Oct. 31, 2020
Derivative notional amount outstanding		$ 3,000,000	₨ 225,000,000
Foreign Exchange Forward Contracts [Member] | Maximum [Member]
Derivative [Line Items]
Date of contracts mature		Jun. 30, 2021
Derivative notional amount outstanding		$ 3,800,000	₨ 280,000,000
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative [Line Items]
Debt instrument interest rate		1.25%	1.25%
1.25% Notes Embedded Cash Conversion Option [Member] | Level 3 [Member] | Fair Value Measurements, Recurring [Member]
Derivative [Line Items]
Fair value liability of embedded cash conversion option					$ 82,800,000

Derivative Financial Instrume_5

Derivative Financial Instruments - Derivatives Instruments Designated as Cash Flow Hedges - (Detail) - Cash Flow Hedging [Member] - Foreign Exchange Contract [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Recognized in OCI	$ 1,280	$ (257)	$ 1,798	$ 83
Cost of revenue [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	107	16	71	76
Selling, General and Administrative Expenses [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	52	12	34	53
Research and development [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	$ 111	$ 19	$ 73	$ 85

Derivative Financial Instrume_6

Derivative Financial Instruments - Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option - (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Derivative Instruments Gain Loss [Line Items]
Net (loss) income included in Other income, net	$ 0	$ 179	$ 101	$ 93
1.25% Call Option [Member]
Derivative Instruments Gain Loss [Line Items]
Net (loss) income included in Other income, net	0	(3,567)	(84)	(6,262)
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative Instruments Gain Loss [Line Items]
Net (loss) income included in Other income, net	$ 0	$ 3,746	$ 185	$ 6,355

Other Comprehensive Income - Co

Other Comprehensive Income - Components of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			$ 1,285,188
Other comprehensive loss (income) before reclassifications			723	$ 26
Net losses (gains) reclassified from accumulated other comprehensive loss			(132)	(158)
Total other comprehensive income (loss)	$ 1,732	$ (799)	591	(132)
Balance at the end of the period	1,208,387		1,208,387
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			(4,392)	(5,584)
Other comprehensive loss (income) before reclassifications			(611)	(35)
Net losses (gains) reclassified from accumulated other comprehensive loss			0	0
Total other comprehensive income (loss)			(611)	(35)
Balance at the end of the period	(5,003)	(5,619)	(5,003)	(5,619)
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			0	195
Other comprehensive loss (income) before reclassifications			1,334	61
Net losses (gains) reclassified from accumulated other comprehensive loss			(132)	(158)
Total other comprehensive income (loss)			1,202	(97)
Balance at the end of the period	1,202	98	1,202	98
Accumulated Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			(4,392)	(5,389)
Balance at the end of the period	$ (3,801)	$ (5,521)	$ (3,801)	$ (5,521)

Other Comprehensive Income - _2

Other Comprehensive Income - Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - Foreign Exchange Contract [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Sep. 30, 2020	Sep. 30, 2019
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)		$ 68	$ 418	$ (34)
Revaluation of tax effects	$ 149	$ 149

Other Comprehensive Income - In

Other Comprehensive Income - Income Tax Effects Related to Components of Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Accumulated Other Comprehensive Income Loss [Line Items]
Foreign currency translation adjustments, Before-Tax Amount	$ 983	$ (574)	$ (611)	$ (35)
Other comprehensive income (loss), Before Tax Amount	1,992	(879)	1,009	(166)
Foreign currency translation adjustments, Tax Effect	0	0	0	0
Other comprehensive income (loss), Tax effect	(260)	80	(418)	34
Foreign currency translation adjustments, Net	983	(574)	(611)	(35)
Derivatives qualifying as cash flow hedges, net gain (loss), Net	749	(225)	1,202	(97)
Other comprehensive income (loss)	1,732	(799)	591	(132)
Derivatives Qualifying as Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount	1,009	(305)	1,620	(131)
Derivatives qualifying as cash flow hedges, net gain (loss), Tax Effect	(260)	80	(418)	34
Derivatives qualifying as cash flow hedges, net gain (loss), Net	749	(225)	1,202	(97)
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Before-Tax, Amount	1,280	(257)	1,798	83
Derivatives qualifying as cash flow hedges, net losses (gains) reclassified into income, Before-Tax Amount	(271)	(48)	(178)	(214)
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount	1,009	(305)	1,620	(131)
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Tax Effect	(330)	67	(464)	(22)
Derivatives qualifying as cash flow hedges, net losses (gains) reclassified into income, Tax Effect	70	13	46	56
Derivatives qualifying as cash flow hedges, net gain (loss), Tax Effect	(260)	80	(418)	34
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Net	950	(190)	1,334	61
Derivatives qualifying as cash flow hedges, net losses (gains) reclassified into income, Net	(201)	(35)	(132)	(158)
Derivatives qualifying as cash flow hedges, net gain (loss), Net	$ 749	$ (225)	1,202	(97)
Other comprehensive income (loss)			$ 1,202	$ (97)

Contingencies - Additional Info

Contingencies - Additional Information (Detail) - Practice Fusion, Inc. [Member] - US Department of Justice and US Attorney [Member]	9 Months Ended
	Sep. 30, 2020USD ($)
Criminal Fine [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount	$ 25,300,000
Forfeiture Payment [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount	959,700
Civil Settlements [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount	118,600,000
State Medicaid Program Expenditures [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount	$ 5,200,000

Business Segments - Additional

Business Segments - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2020Segment
Segment Reporting [Abstract]
Number of operating segments	3
Number of reportable segments	2

Business Segments - Revenues an

Business Segments - Revenues and Income (Loss) from Operations Related to Segment Within Reconciliation to Consolidated Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Segment Reporting Information [Line Items]
Revenue	$ 402,030	$ 406,223	$ 416,713	$ 444,184	$ 444,460	$ 432,049	$ 1,224,966	$ 1,320,693
Gross profit	161,597			175,302			483,042	533,519
Income (loss) from operations:	9,379			3,182			(4,567)	10,570
Unallocated Amounts [Member]
Segment Reporting Information [Line Items]
Revenue	6,745			9,873			24,731	27,797
Gross profit	5,150			6,517			17,042	18,881
Income (loss) from operations:	2,727			3,148			8,594	10,940
Core Clinical and Financial Solutions [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	306,451			343,016			937,882	1,031,210
Gross profit	104,045			115,403			312,901	357,850
Income (loss) from operations:	(8,387)			(9,514)			(45,132)	(26,772)
Data Analytics and Care Coordination [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	88,834			91,295			262,353	261,686
Gross profit	52,402			53,382			153,099	156,788
Income (loss) from operations:	$ 15,039			$ 9,548			$ 31,971	$ 26,402

Supplemental Disclosures - Supp

Supplemental Disclosures - Supplemental Disclosures (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$ 218,701	$ 129,349	$ 129,668
Restricted cash	6,209	9,375	$ 7,871
Total cash, cash equivalents and restricted cash	224,910	138,724
Supplemental non-cash information:
Issuance of treasury stock to commercial partner	$ 752	$ 701

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($) $ in Millions	Oct. 29, 2020	Oct. 15, 2020	Oct. 12, 2020	Jul. 30, 2020
CarePort Purchase Agreement [Member] | WellSky Corp [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Sale of business unit			$ 1,350
EPSi Purchase Agreement [Member] | Senior Secured Term Loan [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Prepayment of debt	$ 20
EPSi Purchase Agreement [Member] | Senior Secured Term Loan [Member] | Second Amended Credit Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Prepayment of debt	$ 19
EPSi Purchase Agreement [Member] | Strata Decision Technology LLC [Member]
Subsequent Event [Line Items]
Sale of business unit				$ 365
EPSi Purchase Agreement [Member] | Strata Decision Technology LLC [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Sale of business unit		$ 365
EPSi Purchase Agreement [Member] | Strata Decision Technology LLC [Member] | Minimum [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Pre-tax gain (loss) on sale of business		225
EPSi Purchase Agreement [Member] | Strata Decision Technology LLC [Member] | Maximum [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Pre-tax gain (loss) on sale of business		$ 235